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Charcot–Marie–Tooth disease is the most common inherited neuropathy and a duplication of the 
peripheral myelin protein 22 gene (PMP22) causes the most frequent sub-form Charcot–Marie–
Tooth 1A (CMT1A). In contrary to the notion that CMT1A manifests in the second decade of 
life, moderate walking disability and electrophysiological abnormalities are usually already 
present during childhood. The early onset and developmental nature of the disease is also 
supported by findings derived from a Pmp22 transgenic rat model for CMT1A (CMT rat), which 
displays a reduced number of myelinated fibers per peripheral nerve already early postnatally 
and never reaches a wildtype level throughout development. RNA transcription analysis has 
revealed that there is a striking continuous upregulation of Schwan cell neuregulin 1 type I 
(NRG1_I) which we could show that it is contributing to the reported hypermyelination of small 
caliber axons in CMT1A rodent models. On the other hand, CMT rat Schwann cells show a 
strongly impaired lipid biogenesis required for myelination as assessed by RNA expression and 
lipid profiling of peripheral nerve transcriptomes and myelin composition, respectively. 
Importantly, Pmp22 overexpressing Schwann cell also reflects an impaired myelination 
competence in vitro, when co-cultured with dorsal root ganglia neurons. A remarkable 
improvement of Schwann cell myelination upon supplementation with phosphatidylcholine in 
vitro has led to the hypothesis that exogenous supplementation with lipids in vivo may improve 
disease progression. Indeed, we observed improved disease progression on the histological, 
electrophysiological and behavioral levels in CMT rats which were fed with a chow enriched in 
lecithin from P2 to adulthood. Moreover, disease amelioration is also visible after late long term 
(P21-P112) and early short term treatment (P2 to P21), but the effect is fading after treatment 
cessation. Therefore, continuously supplying patients with exogenous lipids may be considered 
as a promising therapeutic approach for CMT1A disease. 
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Myelin evolution:   
 
 A big step in evolution is the nervous system development with its subdivion into two major 
divisions; central (CNS) and peripheral nervous system (PNS). While CNS is the higher control 
center, PNS is connecting CNS to peripheral organs 
1,2
. The rapid transmission of electrically 
encoded information is an indispensable requirement for nervous system functioning. Such 
critical function is carried out through highly specialized cells called neurons. In CNS and PNS, 
neurons commonly are extending over long distances enabling signal transmission between 
distant central areas and its peripheral effectors. Therefore, the more big and complex an 
organism is, the more rapid transmission of neural signals becomes necessary as it facilitates 
coordination and processing of complex neuraly encoded information 
3
.  Fast conduction of 
neural signals was achieved evolutionally by two approaches: 1) increasing axonal diameter as in 
the case of Squad axons, 2) axonal insulation in order to enhance membrane resistance and 
reduce membrane capacitance. Vertebrates and some invertebrates have adopted the second 
approach through developing a multilayered structure surrounding the axons called myelin 4,5.  
 
Although its major functions are similar in CNS and PNS, myelin is produced by two distinct 
glial cells in each subtype. In CNS, myelin is produced by oligodendrocytes in which more than 
one segment on the same axon or several axons can be myelinated by the same oligodendrocyte. 
On the other hand, Schwann cells are myelinating PNS axons in a one to one fashion as one 
Schwann cell can myelinate a single segment on an individual axon.   
 
Schwann cell origin and development:  
 
In PNS, neural crest-derived Schwann cell (SC) precursors migrate into the periphery in tight 
association with elongating peripheral axons 
6–8
. Further in development, Schwann cell precursor 
cells evolve into immature Schwann cells which wrap a group of axons 
9
. Later, immature 
Schwann cells send their processes to invade the axonal bundles in order to select and decide to 
myelinate axons, or not, according to their caliber in a process called radial sorting. In this 
process, axons bigger than or equal to 1 µm will be myelinated after becoming associated with a 
single Schwann cell in a one to one fashion. In turn, each Schwann cell will produce a single 
  Introduction 
12 
 
myelin segment, termed internode, along an individual axon and leaving unmyelinated small 
regions in between which are called nodes of Ranvier. On the other hand smaller axons (<1 µm) 
bundles surrounded  by Schwann cell cytoplasm instead of getting myelinated they become 
segregated from each other through ending up in separate pockets in the same Schwann cell 
forming a unique PNS myelin structure called Remak Bundle
10–14
 (Fig. 1).      
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The radial sorting process is one of the phenomenon exhibiting clearly the neuron-glia cell 
interactions which indeed act in both directions. Although axonal sorting and later myelination of 
axons is carried out by immature Schwann cells, the development of Schwann cell depends on 
the axons’ caliber. Such Schwann cell development is mediated by axonal neuregulin-1 type III 
(NRG1-III), a transmembrane protein which controls almost all aspects of Schwann cell biology 
including proliferation, migration and differentiation 
15
. Sorting of an axon results in pushing 
immature Schwann cells  further in the differentiation lineage and lead to the formation of a pro-
myelinating SC-axon unit. Such association is a requirement for myelin sheath-production 
programs activation
16
 via mounting a myelin-specific gene expression program in 
promyelinating Schwann cells
17
. In contrary, immature Schwann cells wrapping small caliber 
Figure 1:The Schwann cell developmental lineage and repair response. The diagram shows the main 
developmental cell types, repair (Bungner) Schwann cell and steps of Schwann cell development. Solid 
arrows indicate developmental steps. Red arrows indicate Schwann cell injury associated transformation 
into repair cell. Dashed arrows indicate post-repair response. E stands for embryonic time points in mouse 
development. (Adapted from K. R. Jessen and R. Mirsky (2016).  
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axons (< 1µm) and not involved in radial sorting becomes non-myelinating Schwann cells 
interchangeably called Remak cells which eventually engulf small caliber axons in individual 
pockets as mentioned before (Fig 1) 
18,19
.              
Regulation of Schwann cell differentiation and myelination by axonal NRG1: 
 
Axonal NRG1 (NRG1_III) is controlling Schwann cell differentiation and myelination through 
three major signaling axes. The first is mediated by NRG1_III dependent activation 
(phosphorylation) of erythroblastic leukemia viral oncogene homolog-2/3 (ErbB2/ErbB3) 
receptor on Schwann cells
15
. This activation leads to activation of PI3K/PIP3/AKT signaling 
which is a major axis of Schwann cell development and myelination. In this axis, phosphorylated 
PI3K catalyze the conversion of PIP3 from PIP2 which in turn phosphorylate AKT; a major 
positive regulator of Schwann cell differentiation and myelination
20
. Another branch of this axis 
is the DLg1/PTEN/AKT which is activated by continuous ErbB2/ErbB3-NRG1_III dependent 
activation. As PTEN reduces AKT activity, it has been shown to be a possible myelination 
termination signal. Therefore the interplay between NRG1, DLg1-PTEN complex and AKT is 
controlling the peripheral nervous system myelination
21
. Of note, AKT promotes myelination via 
cholesterol biosynthesis mediated by sterol regulatory element-binding proteins (SREBPs) 
22,23
.    
 
The second axis is the MEK pathway. Yy1 phosphorylation of MEK is important for Krox20 
induction, Schwann cell differentiation and myelination 
24
.  Moreover Erk1/2 ablation from 
Schwann cell has stopped myelination indicating that it is required for myelination
25,26
. In 
addition, ablation of tyrosine phosphatase SHP2 (Ptpn11; protein tyrosine phosphatase non-
receptor type-11) in Schwann cell has led to reduced Erk1/2 phosphorylation. This is indicating 
that MEK/Erk signaling is part of NRG1/SHP2-regulated myelination axis 
27
. 
 
The third is mediated by Schwann cell stimulation with NRG1 which leads to an increased level 
of intracellular calcium mediated by PLC-g (phospholipase C-g). This in turn leads to nuclear 
translocation of NFATc4 and complex formation with Sox10 which lead to Krox20 and P0 genes 
activation 
28
 .          
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The role of axonal Neuregulin-1in Schwann cell development: 
 
Neuregulin-1 signaling is important for neural crest cells differentiation and consecutive 
Schwann cells development
29,30
. In addition, absence of NRG1 or it receptors ErbB2 or ErbB3 
leads to absence of Schwann cell precursors (SCPs) in the nerve trunk 
31,32
. Indeed, it has been 
shown that NRG1 is crucial for SCPs survival 
9,33
. Unlike the two other isoforms which contain 
immunoglobulin domain and can be resealed from the membrane after cleavage by 
metalloproteases, NRG1_III is a transmembrane protein and act in a juxtcrine manner (Fig.2) 
30,34
. Interestingly, Schwann cell proliferation, migration, differentiation and eventually 
myelination process are controlled by axonal NRG1 (NRG_III) 
35
.     
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
More evidence emphasizing the importance of axonal NRG1_III in controlling Schwann cell 
myelination were concluded from its ablation as well as overexpression in vivo. 
Haploinsufficiency of axonal NRG1 has led to reduction in myelin sheath thickness 
(hypomyelination). On the other hand, overexpression of axonal NRG1 had resulted in an 
increase in myelin sheath thickness (hypermyelination). In addition, lack of axonal NRG1 has 
Figure 2:Schematic structures of major NRG1 isoforms in the nervous system. Unlike type III 
isoform, has two transmembrane domains, other isoforms (I&II) have only one transmembrane domain. 
Proteolytic cleavage in the juxta-membrane area releases the epidermal growth factor (EGF) domain 
containing part of both I&II isoforms while III remain anchored to the membrane. Adaptaed from Jessen 
& Mirsky 2005.  
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resulted in axonal ensheathment defect 
20
. Moreover, NRG1_III has been shown to control 
migration of Schwann cells in the developing nerves to facilitate developmental myelination 
36
.    
 
 
 
 
 
 
 
 
 
 
 
 
 
Taken together, these observations show that axonal NRG1 is important for Schwann cell lineage 
survival, migration, proliferation, differentiation, axonal ensheathment as well as myelin sheath 
thickness in peripheral nervous system (Fig.3)  
30,35
.  
 
Transcriptional and molecular control of Schwann cell development:   
A consequence of axonal sorting is the one to one association of sorted axons with Schwann  
cells. Such association initiates a myelin specific transcriptional program which strictly controls  
Schwann cell differentiation and myelination combining positive as well as negative regulators
37
. 
Schwann cell positive transcriptional regulation:   
 
Early growth response-2 factor (Egr2 known also as Krox20) plays a central role in controlling 
Schwann cell myelination as it activates myelination support genes and represses inhibitor of 
Figure 3:Axonal NRG1 controls various aspects of Schwann cell differentiation and myelin sheath thickness. (a) Neural crest 
precursor cells (green) fate during development is directed by the extent of NRG1 stimulation received from the associated axons 
(yellow and purple). Precursor cells subjected to high NRG1 stimulation of ErbB2/3 receptors are differentiating into myelinating 
Schwann cells while other are forming Remak cell which surround a group of small caliber axons forming a Remak bundle. (b) 
Axonal NRG1 level of expression on the axonal membrane controls myelin sheath thickness. The scheme in b is showing a gradual 
in increase in myelin sheath thickness proportional to the leve of NRG1 on the axonal membrane in a mouse model in vivo. Of not, 
complete loss of axonal NRG1 leads to postnatal death. Adapted from Nave & Salzer 2006.    
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myelination in order to support myelination further
38
. A major Schwann cells positive 
transcription regulator is SRY-related HMGbox- 10 (Sox10) which is central to Schwann cell 
myelination. Sox10 activates octamer-binding transcription factor-6 (Oct6) which eventually 
induces the expression of Krox20 
39
. Another activator of Krox20 is the nuclear factor of 
activated T-cells, cytoplasmic, calcineurin-dependent-4 (NFATc4) in association with Sox10
28
. 
In addition to Krox20 gene activation, NFATc4 activates MPZ gene which encodes myelin 
protein zero; the most abundant myelin protein which is indispensable for myelin sheath 
compaction and stability 
28
.  
             
In agreement with its role in Schwann cell lineage development, NRG1_III activates the nuclear 
factor of k light polypeptide gene enhancer in B cells transcription factor (NF-kB) which has 
been shown to promote myelination via Sox10 gene activation. It is noteworthy that NF-kB 
activity is epigenetically regulated by histone deacetylases HDAC1 and HDAC2
40
. Further 
studies have shown that Sox10 and Krox20 are also regulated by HDAC1 and HDAC2 which 
indeed highlight another level of the myelination process regulation 
41
. 
 
Schwann cell negative transcriptional regulation:   
 
Besides activation of positive myelination transcriptional regulators, suppression of the negative 
regulators must be assured during myelination.  NGFI-A/Egr-binding (NAB) corepressors with 
Krox20 has been shown to associate with the promotors of various myelination inhibitors, 
including inhibitor of DNA binding-2 (Id2), inhibitor of DNA binding-4 (Id4), and  (Ras 
associated with diabetes) (Rad). Such association leads to the suppression of these myelination 
inhibitor genes during myelination 
42,43
. Another major inhibitor of myelination is the 
transcription factor AP-1 component c-Jun (referred to as c-Jun). Therefore, this transcription 
factor is inactivated during myelination process and only activated post injury to promote 
Schwann dedifferentiation 
44,45
.         
 
In addition to NAB and c-Jun, a demyelination inducing transcription factor is the active 
transcriptional regulator Notch intracellular domain (NICD). It exerts its function by inducing 
demyelination post injury after being activated through proteolytic release
46
. Such negative 
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myelination transcription factors are important for inducing Schwann cell dedifferentiation and 
demyelination after injury. These two process have been shown to be important for the repair 
process via helping axonal regrowth and myelinating Schwann cell transdifferentiation to 
support nerve repair in case of acute nerve injury. Moreover, in case of chronic injuries as in 
demyelinating neuropathies these negative regulators are inappropriately activated and 
hampering myelination 
38
.         
 
Post-transcriptional regulation of peripheral nervous system myelination process:  
 
Another level of Schwann cell myelination control is mediated by micro RNAs. The 
posttranscriptional regulation of Schwann cell myelination was concluded from Schwann cell 
specific deletion of Dicer in vivo. In turn, this has resulted in differentiation arrest due to 
disturbance of the regulatory miRNA network 
47,48
.   On the cellular level, Schwann cell Dicer 
specific deletion has led to impairment in radial sorting as well as increased Schwann cell 
proliferation and apoptosis 
48
. Moreover, Dicer deletion has led to impaired axonal integrity 
which indicates a disturbed Schwann cell-axon interaction
47
. On the molecular level, Dicer 
deletion has led to an increase in myelination inhibitors and decrease in myelin positive 
regulators 
47,48
. In line, miRNAs-138 has been shown to suppress the expression of well-
established Schwann cell myelination inhibitors including c-Jun, Sox2 and CyclinD1 in vitro 
49
. 
Taken together, these findings indicate that micro RNAs promote myelination positive regulators 
effect through suppression of the inhibitors which eventually support myelination.         
Lipid biosynthesis pathway: 
 
A consequence of NRG1 dependent-AKT activation is cholesterol biosynthesis which is 
mediated by sterol regulatory element-binding proteins (SREBPs) 
50
. Activation of SREBPs is  
regulated by SREBP cleavage-activating protein (SCAP) which it is activated in response to 
cholesterol abundance in endoplasmic reticulum ER 
50
. Since cholesterol biosynthesis is crucial 
for myelination, SCAP deletion results in absence of SREBP-mediated gene expression involved 
in cholesterol and fatty acid synthesis and leads to impaired myelin synthesis. In addition, 
cholesterol biosynthesis absence has led to hypomyelination and myelin decompaction most 
likely due to a P0 export defect from ER
51
. Moreover, Schwann cell Pmp22 overexpression in 
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Charcot Marie Tooth disease (CMT1A) leads to reduction in lipid biosynthesis genes expression 
and eventually leading reduced cholesterol biosynthesis
52
.  Moreover, disturbed lipid 
homeostasis has detrimental consequences on myelination as accumulation of phosphatidic acid 
(PA), due to a Lpin 1 gene deficiency, abnormally activates MEK–Erk pathway and lead to 
demyelination and aberrant Schwann cell proliferation after myelination initiation 
53
. 
 
Due to the huge required amount of lipids for myelin formation, the myelinating glial cells have 
the ability to synthesize most of the lipids themselves
54,55
. Furthermore, they are able to build up 
myelin even if endogenous lipid synthesis has been shut down but in very low levels 
50
. In turn 
this has led to the conclusion that the myelinating cells can assimilate and use lipids from the 
extracellular environment. Supporting observations for this conclusion were derived from 
transcription analysis in rodents which has showed that the levels of expression of  lipoprotein 
receptors in oligodendrocytes
56
 as well as low density lipoprotein receptor (LDLR) gene in the 
PNS were elevated during myelination
57
 and LDLR gene was found not to be required for PNS 
remyelination
58
   
Myelin sheath: 
Myelin multi-layered Structure: 
Biophysical investigations of nervous system structures with parallel axons such as the sciatic 
nerve in the PNS and optic tract in the CNS revealed that the myelin sheath is characterized by 
having both a lipid dependent and a protein-dependent birefringence
59
. This is in line with the 
fact that myelin sheath is composed of alternating protein and lipid repeating unit which have 
variable spacing distances according to species and tissue type. The spacing distances of the 
electron density plot, depicting the repeat units, presented in figure 4 shows that one repeat unit 
is composed of one bimolecular layer of lipid (about 50 Å) and two protein layers (about 15 Å 
each).  Also, the diagram shows that a two fused repeating units has twice the value of the one 
repeat unit
60
. 
More information about the nature of the detailed structure of myelin was revealed from electron 
microscopy where transverse sections of axons showed myelin as a series of alternating dark and 
less dark lines (protein layers) separated by unstained zones (the lipid hydrocarbon chains). 
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According to electron microscopy micrographs of the myelin sheath, it is characterized by 
asymmetry on protein layers staining. The underlying reason for this asymmetry is the presence 
of less dark, intraperiod lines representing the closely apposed outer protein layers of the original 
cell membrane because the membranes are not actually fused. Moreover, the dark, major period 
line is generated by the fused, inner protein layers of the cell membrane. Interestingly, 
comparison of PNS and CNS myelin electron micrographs revealed that there a constant average 
difference in periodicity; 119 Å average repeat distance in PNS myelin and 107 Å in CNS 
myelin
59
. 
Node of Ranvier: 
The wrapping of the axons with a precisely arranged and integrated multi-layerd myelin sheath is 
indispensible for its function. The myelin sheath high resistance and reduction of the axonal 
membrane resistance due to axon insulation by the myelin sheath
61
, leads to faster conduction 
velocity. This can be perceived upon comparison of the mechanisms of signal conduction 
mechanisms and speed in both myelinated and unmyelinated axons. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4: A diagram depicting some of the ultrastructural features of CNS myelin. The cutaway view of 
myelin and axon shows the nodal and the paranodal regions.  A cross section at the intermodal region 
shows the inner and outer mesaxons and their relationship to the inner cytoplasmic wedges and the outer 
loop of cytoplasm. The right part of the graph shows a rough representation of myelin repeating units’ 
dimensions and appearance as derived from electron micrographs. Next to that, the dimensions derived 
from electron density curve of CNS myelin resulted from X-ray diffraction analysis of freshly ioslated 
nerves. The corresponding components of the peaks and troughs of the curve are drawn below. (Adapted 
from Norton, W. T.The myelin sheath. In E. S. Goldensohn and S. H. Appel (eds), Scientific Approaches to 
Clinical Neurology. Philadelphia: Lea & Febiger, 1977, pp. 259–298159.) 
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When the fibers are unmyelinated, the conduction of a neural signal is propagated through local 
circuits of ion current which flow through the respective channels into the active regions of the 
axonal membrane, in and out the membranes. The formation of such circuits leads to 
depolarization of the next membrane region to continue such process along the axonal 
membrane.        
 
In contrast, myelinated axons are covered with myelin with only regularly spaced regions, called 
nodes of Ranvier, which are not covered with myelin. The nodes of Ranvier are characterized by 
high density of Na
+
 channels and spatially separated from voltage-dependent K
+
 channels 
62
. 
Upon membrane excitation, the generated local circuits cannot flow through the myelin the 
sheath due its high resistance and flow inside the fibers and depolarizes the membrane at the next 
node. Due the low capacitance of the myelin sheath, little energy is required to depolarize the 
internodal region which leads to an increase in the speed of local circuit spreading. Such 
spreading and speeding up leads propagation of the neural impulse which is called saltatory 
conduction. This speeding up of the depolarization wave is highly rapid than in myelinated 
axons. To ensure such high conduction velocity and use energy efficiently, nodes must be 
properly spaced. Moreover, restriction of ions flow to the nodal area leads to a reduction in the 
overall sodium in flux inside the fibers and eventually the nerve (Fig.4).                
Paranodal regions and Schmidt- Lantermann clefts: 
A common feature of the paranodal regions and the Schimdt-Lantermann clefts is that they are 
cytoplasm filled connected with the Schwann cell cytoplasm, uncompacted regions and found in 
each layer of the myelin sheath. A specific feature of the paranodal regions is their position at the 
edges of the myelin sheath. As myelin is separated from the axons by periaxonal space, the 
lateral loops together with axolemma form membrane complexes which are called transverse 
bands in order to seal the myelin to the axolemma. In contrast to lateral loops, Schmidt- 
Lantermann incisions are in the middle regions of the myelin sheath rather than at the edges
63
.      
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The characteristic composition of myelin sheath: 
A high lipid-to-protein ratio is a unique characteristic of the myelin sheath that distinguishes it 
from other membranes. Lipids in myelin membranes, accounts for approximately 70% of myelin 
membrane dry weight shown in myelin biochemical purification via sucrose gradient 
centrifugation
64
. Myelin membrane has characteristic myelin-specific proteins which I will 
describe some of them and their contribution to the building up and function of the myelin 
Sheath.   
Myelin lipid composition: 
Although, myelin membrane has no myelin-specific lipids, it has a characteristic lipid 
composition. The myelin membrane contains a high level of cholesterol of at least 26% by 
weight
64,65
 and is enriched in galactolipids (31% vs. 7% for liver cell plasma membranes). In 
addition monogalactosylsphingolipidscerebroside and sulfatide , account for 14%–26% and 2%–
7% of myelin lipids respectively. Myelin is also characterized by high  levels of saturated long-
chain fatty acids. Plasmalogens (etherlipids) is one of the enriched lipid classes in myelin which 
comprises 70% of the total phosphatidylethanolamine in white matter while it contributes to only 
5% in liver
66,67
.  
Effect of Lipids biochemical properties on myelin membrane function: 
Intriguingly, the function of the myelin membrane is affected by the biochemical properties of 
the incorporated lipids
68
. For instance, cholesterol, the most important regulators of lipid 
organization in the membrane, plays a critical role in establishing the proper membrane fluidity 
and ion permeability. These properties are critical for the insulating function of the myelin 
membrane
69
. The membrane fluidity is decreased due to the increased ordering of fatty acids 
tails. This is mediated by alignment of the cholesterol rigid body alongside the fatty acid tails 
leading to reduction of polar molecules permeability
70–73
. Moreover, increased fatty acids tails 
ordering slows down membrane proteins diffusion and decreases membrane pending 
capacity
70,71,74,75
. The tight binding of some proteins to cholesterol indicate that it is involved 
myelin protein translocation
76
. 
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Lipids are essential for myelin assembly, proper backing and insulation: 
In addition to their structural role, myelin enriched lipids contributes to the appropriate myelin 
membrane assembly, the proper backing and the insulating property of myelin membrane 
68
.  
Myelin membrane proper backing is achieved by synchronized protein lipid interaction and the 
importance of such cooperation has been derived from mutation studies 
77
. The perturbed 
endogenous Schwann cell lipid metabolism in SCAP conditional knockout mice is accompanied 
by myelin backing ultrastructural defects due to increase in the unsaturation level of fatty acids 
in myelin 
50
. The insulating properties of myelin membrane is mediated by the electric insulation 
the outer layer by glycolipids which is composed of thick and ordered layers of long saturated 
fatty acids which is further sealed by another layer of cholesterol 
50
. 
Myelin lipids role in myelin proteins sorting and localization: 
In addition to their structural and biophysical membrane properties role, myelin lipid are 
essential for myelin protein trafficking and myelin assembly
55,78
. In the CNS, a proof of principle 
of such role came from certain PLP mutations which resulted in perturbed cholesterol and PLP-
lipid rafts interaction, a cause of dysmyelination in spastic paraplegia
79
. In the PNS, a partial 
mislocalization of myelin protein P0 due to disturbed Schwann cell cholesterol biosynthesis 
resulted in noncompaction of the myelin membrane and hypomyelination
55
. Furthermore, in cell 
culture experiments, defects due to disturbed myelin protein P0 mislocalization could be restored 
by cholesterol or lipoprotein supplementation. In turn this is highlighting the essentiality of 
myelin protein P0 cholesterol recognition motif for the correct trafficking from endoplasmic 
reticulum to the newly synthesized  myelin sheath 
50,55
.       
Myelin lipids regulate myelinating glial cell differentiation: 
In the CNS, galactosphingolipids were suggested to be regulators of oligodendrocytes 
differentiation. This regulation is thought to be carried out via two pathways. 
Galactosphingolipids can play a direct role in cell adhesion necessary for correct timing of 
oligodendrocyte (OL) differentiation or via disturbing oligodendrocyt’s differentiation indirectly 
through affecting plasma membrane signaling proteins
80
. In the PNS, phosphatidic acid (PA) was 
shown to activate Schwann cell de-differentiation via activation of the MEK-Erk pathway. This 
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is line with the observed demyelination in Lpin1 mutant mice which was shown to be mediated 
by an increase of PA levels
53
 due to the absence of  Lpin1 activity. 
Myelin specific proteins: 
In contrast to usual myelin lipid composition, myelin sheath is characterized by a specific set of 
proteins. Although there are some proteins shared by the CNS and PNS myelin, some are 
specific for CNS or PNS.  The PNS is characterized by a set of proteins including myelin protein 
zero (MPZ), myelin basic protein (MBP), P2 protein, Connexin32 and peripheral myelin protein-
22 (PMP22). 
Protein Zero (P0)/ Myelin Protein Zero (MPZ): 
MPZ is a transmembrane, with only one transmembrane domain and is 30 kDa, glycoprotein 
with an immunoglobulin like domain. Since it is the most abundant protein in the myelin sheath 
it accounts for approximately 50% of the proteins in PNS myelin 
81
. Rat MPZ has a single 
extracellular Ig-like domain consisting of 124 amino acids form two domains, the first is a 
hydrophobic transmembrane domain consisting of 26 amino acids and the second is an 
intracellular domain consisting of 69 amino acids
82,83
. Moreover, MPZ is post-translationally 
modified via glycosylation with many heterogeneous glycans. In addition, phosphorylation and 
acylation if MPZ were previously described 
59
.  
In contrast to CNS, PNS myelin is characterized by greater separation of extracellular surfaces in 
myelin due to the relatively large, glycosylated, extracellular Ig-like domain of MPZ. By 
comparing the overall protein composition, in the PNS MPZ is the most abundant protein and 
PLP is the major protein in CNS. Although MPZ and PLP are different with respect to amino 
acid sequence, post-translational modifications and membrane topology, they play similar roles 
in myelin structure formation
67
. In addition to its crucial role in myelin compaction, MPZ has 
been shown to play a role in cell–cell interactions. This is due to tetrameric homophilic binding 
of MPZ extracellular domains indicating that P0 stabilizes the intraperiod line of PNS myelin by 
similar hemophilic binding
84,85
.  
 
Mutation studies revealed that different mutations in the MPZ gene cause dominant 
demyelinating, dominant axonal, and intermediate forms of inherited neuropathies. According to 
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the observed phenotypes, MPZ Mutations could be clustered in two major groups
86
. The first 
group of mutations is characterized by severe phenotypes, affects myelination during 
development, cause early onset neuropathy and affects mainly myelin compaction. This 
phenotype is a result of blocking of the mutated MPZ transport to the plasma membrane or 
myelin membrane disruption by dominant-negative interactions between the mutated and wild-
type MPZ protein 
86,87
. The second group of mutations is mainly axonal phenotypes causing a 
late-onset neuropathy. The underlying patho-mechanisms of such mutations are not clear, it is 
suggested to be mediated by disruption of mutant MPZ expressing Schwann cell–neuron 
interactions leading to axonal degeneration and loss
86
.       
 
Myelin Basic Protein (MBP): 
A remarkable interest in MBP was developed previously because it was first myelin antigen used 
to induce experimental autoimmune encephalomyelitis (EAE) after its injections in animals 
88
.  In 
PNS myelin, MBP has a variable percentage of the total myelin protein while in CNS it ls 
approximately 30% 
89
. Although it is a minor protein in the myelin sheath, the MBP gene has 
seven exons in the full length gene. Phylogenetic analysis has shown that MBP gene is conserved 
in many species and alternatively spliced to produce various isoforms
90–92
.  It has been found that 
isoforms abundance was changing with age as the 14 KDa and 17 KDa MBP and was abundantly 
found in mature rodent tissues while the 18.5 kDa isoform was abundant in CNS.    
It is noteworthy that since MBP is translated locally and therefore MBP mRNA is localized in 
the myelin processes. In turn the translated MBP get incorporated with the membrane directly 
after its synthesis
93
. Interestingly, the PNS shiverer mutant mouse has normal myelin, with 
respect to amount and compaction, in absence of MBP 
94
. This inessentiality of MBP to PNS 
myelination can be explained by the presence of P0 cytoplasmic domain which can stabilize the 
major dense line of PNS myelin alone. The involvement of MBP in PNS myelin compaction was 
revealed from the P0-MBP-double deficient animals, as they have shown more sever compaction 
defect phenotype, in PNS myelin, than that of P0-null mice
83
. 
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Peripheral myelin protein-22 (PMP22): 
PMP22 is, a small hydrophobic protein with four transmembrane domains  (22kDa), two of them 
are extracellular loops and only one of them is glycosylated
95
. Although ubiquitously expressed, 
PMP22 comprise 2–5% of  myelin protein content in Schwann cells and is characterized by its 
tendency to oligomerize 
96,97
. In addition to its structural role in myelinating Schwann cells, 
PMP22 has divers functions in various cell types: 1) It promotes cell spreading, cell migration, 
and apoptosis
98,99
. It is also a component of the developing blood–nerve and blood–brain barriers 
at intercellular junctions
96,100
. It plays a crucial role in proper myelination and myelin 
maintenance and its absence leads to delayed onset of myelination
101
. 3) At later stages, mice 
develop a focal hypermyelinating structures, tomacula, which eventually degenerate with at latter 
age and lead to demyelination
102
 .   
 
Disturbance of PMP22 expression leads to different neuropathies as the type of the disease vary 
according to the gene dosage.  For example, the hereditary neuropathy with liability to pressure 
palsies (HNPP) is caused by PMP22 haploinsufficiency
103
. This is a recurrent neuropathy that is 
characterized by minor trauma of  the peripheral nerves and tomacula formation 
104
. On the other 
hand, duplication of the region containing the PMP22 gene on chromosome 17p11 leads to the 
development of Charcot-Marie-Tooth disease 1A (CMT1A) which is the most common form of 
inherited demyelinating neuropathy
105
.  Furthermore, PMP22 was established as the disease 
causing gene by many transgenic experiments
106–108
.   
 
More importantly, PMP22 over-expression may overwhelm the rapid degradation of, short-life, 
newly synthesized PMP22
109
 through the ubiquitin–proteasome pathway before reaching the 
Schwann-cell plasma membrane
110,111
. The observed accumulation of intracellular vacuolar 
structures due to PMP22 overexpression in vitro, indicated a failure of proteasomal degredation 
process
112,113
. Another consequence of PMP22 overexpression is the formation of microtubule 
(MT)-dependent ubiquitinated PMP22 aggregates called aggresomes
111
. This eventually leads to 
autophagy activation which help degrading of these aggresomes
111
. 
 
Another disease mechanism mediated by PMP22 over-expression is inducing the formation of 
actin/ phosphatidylinositol (4,5)-bisphosphate (PI-4,5-P2)-positive vacuoles
113
. This results in 
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trapping of membrane proteins by altering ADP ribosylation factor-6 (Arf6)-regulated 
endosomal– plasma membrane recycling. Taken together, PMP22 overexpression leads to 
disturbed intracellular degradation of membrane components which in turn may lead to aberrant 
turnover of other proteins or membrane lipids
113
 which may be a link for a pathomechanism. .  
The function of low overexpression (as in CMT1A) is, however, still unknown and under 
investigation (pers. communication M, Sereda). 
 
Interestingly, other myelin related diseases are caused by PMP22 missense mutations. Most of 
these mutations affect hydrophobic domains of the protein and lead to the development of more 
severe phenotypes compared with PMP22 overexpression which are known as Dejerine-Sottas 
syndrome
105
. In the course of this disease, the mutant protein is retained in the endoplasmic 
reticulum (ER) and fail to reach the cell surface
114,115
.  Such retention of the mutant PMP22 may 
prevent a proportion of wild-type PMP22 can from transport to the cell membrane by a dominant 
negative mechanism, as the mutant and wildtype PMP22 can make can form homo- and 
heterodimers and multimers 
96,116
. Other studies showed that such transport blocking mechanism 
is not dominant for all proteins, but it was reported that mutated PMP22 proteins exert a 
deleterious effect in the absence of wildtype PMP22
103
. The toxic gain of function of mutant 
PMP22 could be explained by several mechanisms. The first proposed mechanism is based on 
interaction between PMP22 and P0 which might affect the intracellular trafficking of both 
proteins. This suggested mechanism was undermined due to the limited interaction of the two 
proteins
117
. The second suggested mechanism is the general defect in protein biosynthesis via 
deleterious sequestrateion of calnexin, an ER-resident chaperon, due to its interaction with 
mutated, ER-retained PMP22
118
. The third suggested mechanism is via activation of the unfolded 
protein response in ER. This response is triggered by accumulation of mutant PMP22 as 
suggested for the retained proteolipid protein (PLP) mutants
119
  but experimental evidence for 
this mechanism is lacking.  
 
Further insights of the pathomechanisms of PMP22 missense mutations, which next to an altered 
PMP22 gene dosage also triggers neuropathy, have been revealed form analysis of animal 
models
120,121
. In mutant Schwann cells, the endosomal-lysosomal pathway
109
  and ubiquitination 
111
 are upregulated. Furthermore, PMP22- containing aggresomes 
96,111
 and myelin-like figures 
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118
, representing autophagic vacuoles
122
 are present in mutant Schwann cells. The impaired 
proteasome activity and accumulated ubiquitinated substrates, in PMP22 mutant animals, 
indicate that aggresome formation is harmful by failure to remove toxic misfolded PMP22
121
. 
Charcot-Marie-Tooth (CMT) disease 
 
Charcot-Marie-Tooth (CMT) disease is a heterogeneous group of motor and sensory 
neuropathies which constitute the most common inherited PNS disorders with a prevalence of up 
to 1 in 2500
123,124
. It is a slowly progressive disease and results in axonal loss and thereby leads 
to distally pronounced muscle atrophy accompanied with weakness. At later stages, patients 
suffer from sensory impairments and walking disabilities, occasionally leading to wheel chair 
boundness
125–128
. 
 
The nerve conduction velocity (NCV) value is implemented in the discrimination of 
demyelinating CMT type 1 (CMT1), the most common CMT form with strongly reduced NCV 
(38 m/s) from the axonal CMT type 2 (CMT2) with normal or slightly reduced NCV
129
. 
 
Due to disease heterogeneity, several Schwann cell gene mutations can cause CMT1 disease
130
. 
CMT1A (PMP22 duplication,
131,132
, CMT1B (P0 mutations,
133
, CMTX (CX43 mutations,
134
  and 
a less common subtype caused by point mutations in early growth response gene 2 (EGR2,
135
)are 
the major subtypes of CMT1. This genetic classification of disease subtypes, which results in 
similar clinical phenotypes, was found to be insufficient. Therefore, the recent classification 
relies on combining the genetic basis and the characteristic clinical symptoms for a more reliable 
classification system
136
.  
 
Since studying such inherited neuropathies is difficult in to be conducted in humans, availability 
of disease animal models is essential. Therefore the accumulated knowledge, derived from CMT 
animal models during the last two decades, has improved the understanding of the disease 
greatly. A model of choice for mild CMT1A disease subtype is the human PMP22 YAC 
transgenic mouse line (C61 het line) which harbor four transgene copies and has up to 2-fold 
PMP22 mRNA overexpression
137
. It recapitulates the most common CMT1A phenotypes 
including demyelination, concentric layers of multiple promyelinating Schwann cells around 
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naked axons (onion bulbs) and secondary axonal loss
136
. However, a Pmp22 transgenic rat model 
(the CMT1A rat) best mirrors human pathology and clinical features of CMT1A patients
108
 . The 
low level of Pmp22 gene overexpression leas to slowly progressive neuropathy with impaired 
motor functions and reduced  nerve conduction velocity (NCV)
108
. Furthermore, time line 
histological evaluation of disease hallmarks in peripheral nerves has revealed that it remarkably 
resembles the human situation with respect to reduction in myelinated axons numbers, 
hypomyeliantion of large caliber axons, hypermyelination of small caliber axons as well as onion 
bulb development
138
.       
 
Therefore, throughout this thesis work I have studied the CMT1A disease progression using 
combined omics approach in order to define some of the critical players involved in disease 
progression. Furthermore, by taking the advantage of the availability of various rodent models, I 
have aimed to exploit the defined disturbed myelin related processes for designing and 
conducting experimental therapy trials in order to ameliorate CMT1A disease progression.
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Materials: 
 
Chemicals and consumables  
Except otherwise stated all chemicals and consumables are purchased from Sigma-Aldrich, 
Merck, Serva, Falcon, Eppendorf and Invitrogen. 
General  
 
 
BSA  BioMol 
Ketamine, 10%  CP-Pharma 
Low fat milk powder  Frema 
 
Electron microscopy  
 
 
Azur II  Merck 
Eukit  Kindler / Science Services 
Formvar Plano  
Glutardialdehyde Electron Microscopy Science (EMS) 
Glycid ether 100  Serva 
Lead citrate  Merck 
Methylnadic anhydride  Serva 
Methylene blue  Merck 
Osmium tetraoxide Science Services 
Propylene oxide  Serva 
Polyvinylpyrrolidone (PVP filler)  Sigma-Aldrich 
2,4,6-Tris(dimethylaminomethyl)phenol  Science Services 
Uranyl acetate  SPI-Chem 
 
Protein biochemistry  
 
 
Acrylamide  Serva 
Ammonium persulfate (APS)  BioRad 
Bromphenol blue  Sigma 
cOmplete Mini (Protease inhibitors)  Roche 
Formaldehyde 37%  Merck 
Glycine  Sigma 
2-Mercaptoethanol  Fluka 
PhosStop (Phosphatase inhibitors)  Roche 
Prestained Page Ruler Plus  Fermentas 
SDS (Dodecylsulfate sodium salt)  Serva 
TEMED  Serva 
Trizma Base  Sigma 
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Tween20 (Polysorbate)  Merck 
 
Molecular biology  
 
 
Agarose  AppliChem  
GelRed Biotrend 
GenRuler 100 bp DNA ladder  Fermentas 
GoTaq polymerase  Promega 
Power SybrGreen Applied Biosystems 
Trizol Reagent  Invitrogen  
Superscript III-reverse Transcriptase  Invitrogen  
 
 
Immunohistochemisty 
 
 
Aqua Polymount Polysciences 
Goat serum  Gibco 
Haematoxylin (hemalum solution)  Merck 
Horse serum  Gibco 
Paraformaldehyde, pure  Serva 
 
Consumables  
 
 
Copper grids (100Mesh, Guitarr, Slot)  Gilder Grids  
Coverslips  Thermo Scientific Menzel-Gläser 
Histobond slides  Marienfeld 
PVDF Western Blotting membranes  Roche 
Superfrost Plus slides  Thermo Scientific Menzel-Gläser 
 
Kits 
 
 
Agilent RNA 6000 Nano Kit  Agilent 
DC Protein Assay Kit  BioRad 
Genomic DNA-Isolation Kit  Nexttec 
GoTaq DNA polymerase  Promega 
RNeasy Mini / Micro Kit  Qiagen 
SuperScript III Reverse Transcriptase  Invitrogen 
Vectastain Elite ABC Kit  Vector 
Western Lightning Plus ECL  Perkin Elmer Life Sciences 
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Machines  
 
 
AFS II  Leica 
Agilent 2100 Bioanalyzer Agilent 
Axiophot Observer inverted  Zeiss 
Centrifuge 5415R  Eppendorf 
Diamond knife Histo (45º/Ultra 45°)  Diatome 
Embedding center AP280-1/2/3  Microm 
EMTP (Epon infiltration)  Lynx 
EM900  Zeiss 
EM912AB  Zeiss 
HPM100  Leica 
IntasChemoStar(a luminescence Imager  
348) 
Intas Science Imaging 
IntasChemoStar (Western Lightning Plus-347 
ECL, Enhanced Chemiluminescence Substrate) 
Perkin Elmer 
Light Cycler 480  Roche 
NanoDrop200 Spectraphotometer Thermo Scientific  
Optima TLX Ultracentrifuge  Beckman 
Precellyse24  Bertin Technologies 
PCR-machine  PeqLab 
Sled microtome  Microm 
Thermomax microplate reader  MGW Biotech 
Tissue Processor HMP110  Microm 
Ultracut Leica  
UV illuminator  Intas 
Wet Chamber Blotting System  BioRad 
7500 Fast Real-Time PCR System  Applied Biosystems 
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Solutions and buffers  
Avertin 
 2,2,2-Tribrome ethanol 99%  2% [w/v] 
 Amyl alcohol  2% [v/v] 
 Mix at 40°C for 30 min while stirring. To be filtered before storage at -20°C.  
   
Anesthetic 
 Xylazinhydrochloride (Rompun, BayerVital)  8 mg 
 ketaminhydrochloride  (Ketamin, WDT)  100 mg 
  
Intraperitoneal injection of 8 mg Xylazinhydrochloride and 90 mg 
ketaminhydrochloride per kg of  bodyweight per mouse.  
   
1x Phosphate buffered saline (PBS)  
 
 Sodium chloride  170 mM 
 Potassium chloride  3.4 mM 
 di-Sodium hydrogen phosphate  4 mM 
 di-Potassium hydrogene phosphate  1.8 mM 
 Adjust to pH 7.4 with 1 N NaOH. 
  
Fixatives 
 
16% Paraformaldehyde (PFA stock solution)  
 
 Paraformaldehyde  16% [w/v] 
 Stir for 20 min at 60°C and subsequently increase pH with NaOH to allow full 
dissolution. Store at -20°C. 
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4% PFA in PBS (Fixative) 
 
 Paraformaldehyde  4% [v/v] 
 Phosphate buffer  0,1 M 
 Sodium chloride  0,8% [w/v] 
 Adjust pH to 7.4 before use. 
   
K&S fixative (according to Schultz and Karlsson, 1965)  
 
 16% Paraformaldehyde  25% [v/v] 
 Glutardialdehyde 2,5% [v/v] 
 0.2 M phosphate buffer  50% [v/v] 
 Sodium chloride  0,08 M 
 Adjust pH to 7.4 before use 
   
 
Molecular biology (PCR, cDNA, qRT-PCR)  
 
dNTPs (50x stock solution) 
 
 dATP, dGTP, dCTP, dTTP (Boehringer, 
Mannheim)  
25 mM 
 
 
TBE 20x (stock solution)  
 
 TrisBase 1.8 M 
 Boric acid  1.8 M 
 EDTA 200 mM 
   
Protein biochemical solutions 
 
Sucrose buffer (Homogenisation)  
 
 Sucrose  320 mM 
 Tris-HCl pH 7.4  10 mM 
 Sodium hydrogen carbonate  1 mM 
 Magnesium chloride  1 mM 
 Add proteinase inhibitors and optionally phosphatase inhibitors before use. 
Running buffer (Laemmli buffer working solution)  
 
 TrisBase 25 mM 
 Glycine  192 mM 
 SDS  1% [w/v] 
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Transfer buffer (1x for wet chamber blotting)  
 
 TrisBase 48 mM 
 Glycine  39 mM 
 Methanol 20% [v/v] 
   
Tris buffered saline with Tween20 (TBST)  
 
 Tris-HCl (pH 7.4)  50 mM 
 Sodium chloride  150 mM 
 Tween20  0.05% [v/v] 
   
Protein loading dye (6x)  
 
 Glycine  40% [w/v] 
 Tris-HCl pH 6.8  240 mM 
 SDS  8% [w/v] 
 Bromphenole blue  0,04% [w/v] 
   
 
 
SDS separation gel  
 
 Acrylamide / Bisacrylamide 29 : 1  10-16% [v/v] 
 Tris-HCl pH 8.8  0,4 M 
 SDS  0,1% [w/v] 
 Ammonium persulfate  0,03% [v/v] 
 TEMED 0,08% [v/v] 
   
SDS stacking gel  
 
 Acrylamide / Bisacrylamide 29 : 1  4% [v/v] 
 Tris-HCl pH 6.8  125 mM 
 SDS  0,1% [w/v] 
 Ammonium persulfate  0,05% [w/v] 
 TEMED 0,1% [w/v] 
   
Sucrose solution for myelin purification  
 
 Sucrose  0.29 M 
 Sucrose  0.85 M 
 Add protease inhibitors to the solutions.  
   
Gel fixative (for silver and coomassiestainings)  
 
 Ethanol  40% [v/v] 
 Acetic acid 10% [v/v] 
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Solutions for electron microscopy 
 
Reynolds lead citrate solutions (Reynolds, 1963)  
 
 Lead nitrate  1.33 g 
 Sodium citrate  1.76 g 
 Dissolve in 30 ml ddH2O while shaking. After 30 min add 8 ml of 1 M NaOH to 
adjust the pH to 12. Add ddH2O to 50 ml. Sterile filter before use. 
   
Uranyl acetate  
 
 Uranyl acetate  4% [w/v] 
 Aqueous solution has to be filtered before use. 
   
Epoxy resin (Epon)  
 
 21.4 g Glycid ether 100   
 14.4 g DDSA (Serva, 20755)   
 11.3 g MNA (Serva, 29452)   
 Stir for 10 min and subsequently add 0.84 ml DMP-30. Stir for another 20 min. 
   
Formvar solution  
 
  
 Formvar  1.25% [w/v] 
 Chloroform  50 ml 
 Stir for at least 30 min. Protect from light. Store at room temperature. 
   
Richardson’s Methylene blue / Azure II blue (Richardson et al., 1960)  
 
 Azure II in ddH2O (Stock solution 1)  1% [w/v] 
 Methylene Blue in 1% Borax (Sodium 
borate) (Stock solution 2)  
1% [w/v] 
 Mix equal amount of stock solutions and filter before use. 
 
 
  
Histological staining solutions 
 
Tris buffer (50 mM, pH 7.6)  
 
 Tris-HCl pH 7.6  50 mM 
 Sodium chloride  0.9% [w/v] 
 Prepare freshly and adjust pH to 7.6. 
 
 
  
 
Tris buffered milk ( Blocking solution)(TBS / milk) 
 
 Tris-HCl pH 7.6  50 mM 
                                                                                                                              Materials and Methods 
37 
 
 
 
Table 1: Antibodies 
    
Primary antibodies: 
  
Antibody  Company source Dilution (for WB unless 
otherwise stated) 
Actin  Sigma #A3853 mouse  1 : 5000 
AKT  Cell signaling #4691  rabbit  1 : 1000 
p-AKT  Cell signaling #3787  rabbit  1 : 1000 
Caspr Neuromab (#P97846)  mouse 1 : 750 (WB) / 1 : 200 (IHC) 
GAPDH  Stressgene #CSA-335  
 
mouse  1 : 5000 
    
MAPK  Cell signaling #4695  rabbit  1 : 1000 
p-MAPK  Cell signaling #9101  rabbit  1 : 1000 
MBP  Dako #A0623  rabbit 1 : 5000 (WB) / 1 : 500 (ICC) 
MBP  Serotec (#MCA409S)  rat  1 : 500  
MAG Chemicon #MAB1567  mouse  1 : 500 (WB) / 1 : 50 (IHC) 
Nav1.6  Alomone Labs (#ASC009)  rabbit  1 : 500 (IHC) 
Tuj1 (tubulin beta III)  Covance (#PRB-435P)  rabbit  1 : 400 (ICC) 
    
Secondary antibodies 
Mouse-HRP  Dianova (#115-035-003)  goat  1 : 5000 (WB) 
Rabbit-HRP  Dianova (#111-035-003)  goat  1 : 5000 (WB) 
Mouse-A488  Invitrogen (#A21202)  donkey  1 : 2000 (IHC) 
Mouse-A555  Invitrogen (#A31570)  donkey 1 : 2000 (IHC) 
Rabbit-A488  Dianova (#711-545-152)  donkey  1 : 2000 (IHC)  
Rabbit-A555  Dianova (#111-545-144)  donkey  1 : 2000 (IHC) 
Rat-Dyelight 633 YoProteins (#309) donkey  1 : 500 (IHC) 
 Sodium chloride  0.9% [w/v] 
 Low fat milk powder  2% [w/v] 
 Stir for 20 min at room temperature and filter before use. 
   
Blocking solution (TBS / BSA)  
 
 Sodium dihydrogen phosphate  40 mM 
 Disodium hydrogen phosphate  160 mM 
 Sodium chloride  1.8% [w/v] 
 Bovine serum albumin  1.0% [w/v] 
   
   
Blocking buffer for teased fiber staining 
 
 10% [v/v] Horse serum   
 0.1% [v/v] Tween20   
 Add freshly to phosphate buffered saline (1x PBS). 
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Primers:  
All oligonucleotides were synthesized by the AGCT-laboratory of the Max Planck Institute for 
Experimental Medicine. 
 
Genotyping primers: 
 
CPMP line genotyping primer(rat model genotyping): 
 
 
Fwd.:5'-CCAGAAAGCCAGGGAACTC-3' 
 
Rev.:5'-GACAAACCCCAGACAGTTG-3' 
   
Cspp line genotyping primer(mouse model genotyping): 
 
 
Fwd.: 5'-TCAGGATATCTATCTGATTCTC-3' 
 
Rev.:5'-AAGCTCATGGAGCACAAAACC-3' 
   
Double mutant mouse model (Pmp22 tg::Nrg1fl/fl::DhhCre) primers: 
 
In addition to the Cspp line genotyping primer: 
 
DHHC  
 
 
Fwd.: 5'-CCTGCGGAGATGCCCAATTG-3' 
 
 
Rev.:5'-CAGCCCGGACCGACGATGAA-3' 
Nrg1 flox/flox Fwd.:5'-TCCTTTTGTGTGTGTTCAGCACCGG-3' Rev.: 5'-GCACCAAGTGGTTGCGATTGTTGCT-3' 
 
qRT-PCR primer 
  
   
Mouse primers:   
Rplp0(mouse): 
Fwd.:5'-GATGCCCAGGGAAGACAG -3' Rev.: 5'-ACAATGAAGCATTTTGGATAATCA -3' 
Ppia (CyclophilinA): 
Fwd.:5'-CACAAACGGTTCCCAGTTTT -3' Rev.: 5'-TTCCCAAAGACCACATGCTT -3' 
Nrg1-I(mouse): 
Fwd.:5'-GGGAAGGGCAAGAAGAAGG -3' Rev.:5'-TTTCACACCGAAGCACGAGC -3' 
Nrg1-II(mouse): Fwd.: 5'-CCTCGTTTCCTCCGCTG -3' 
Rev.: 5'-GACTCCTGGCTTTTCATCTCTT -3' 
Nrg1-III(mouse): Fwd.: 5'-ACTCAGCCACAAACAACAGAAAC -3' 
Rev.: 5'-GAAGCACTCGCCTCCATT -3' 
   
Rat primers:   
Nrg1-I: Fwd.:5'-GGGAAGGGCAAGAAGAAGG -3' Rev.: 5'-TTTCGCACCGGAGCACTAGC -3' 
Rplp0: Fwd.:5'-GATGCCCAGGGAAGACAG -3' 
Rev.:5'-CACAATGAAGCATTTTGGGTAG-3' 
Ppia(CyclophilinA): Fwd.: 5'-GTGTTCTTCGACATCACGGCT-3' Rev.: 5'-TCCCCAGTGCTCAGAGCAC-3' 
Fasn: 
Fwd: 5'-GTCCACCCCAAGCAGGCACA-3' Rev.:5'-ACTCACACCCACCCAGACGC-3' 
Pla2g4a: 
Fwd: 5'-CGGTGTCCTCTGCCTCTC-3' Rev.:5'-CGTATGGACTAAATTCTACCCAATC-3' 
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Hmgcr: 
Fwd: 5'-CAACCTTCTACCTCAGCAAGC-3' Rev.:5'-CACAGTGCCACATACAATTCG-3' 
cJun : 
Fwd: 5'-CCTATACTCATACCAGTTCGCACA -3' Rev.: 5'-CGACAACTGTCCCCTCCTC -3' 
Oct6 (Pou3f1): 
Fwd: 5'-TGGGAACCATGTAAATATGTGAGA -3' Rev.: 5'-CCAAAAATAAAAACCAAGCACAA -3' 
Krox20: 
Fwd: 5'-CTACCCGGTGGAAGACCTC -3' Rev.: 5'-TCAATGTTGATCATGCCATCTC-3' 
Mpz: 
Fwd: 5'-GCTGCCCTGCTCTTCTCTT -3' Rev.: 5'-TTTCCCTGTCCGTGTAAACC -3' 
Chka: 
Fwd: 5'-TCCTTGCCAGACTCCATAGC -3' Rev.: 5'-AACACTCTCCAGAACCATTGC -3' 
MBP: 
Fwd: 5'-GGCACGCTTTCCAAAATCT -3' Rev.:  5'-CCATGGGAGATCCAGAGC -3' 
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Methods: 
 
Animals  
 
All animal experiments were conducted according to the Lower Saxony State regulations for 
animal experimentation in Germany as approved by the 
NiedersächsischeLandesamtfürVerbraucherschutz und Lebensmittelsicherheit (LAVES) and in 
compliance with the guidelines of the Max Planck Institute of Experimental Medicine. Animals 
were kept in a 12h-light-dark-cycle and all handling and investigations were carried out in the 
light phase.  
 
Pmp22 transgenic rats 
108
, (SD-Tg(Pmp22)Kan) were used for RNAseq, disease progression 
analysis and phospholipids experimental therapy trials. Pmp22 transgenic mice 
(Tg(PMP22)C61Clh), Pmp22 transgenic-Nrg1 knockout mice (PMP22 tg::Nrg1fl/fl::DhhCre) 
and wild type-Nrg1 knockout (Nrg1fl/fl::DhhCre) were used for the evaluation of the Schwann 
cell NRG1 contribution in CMT1A disease progression.In addition, mice embryos were used for 
in vitro experiments. Animals were obtained from heterozygous breedings. Whenever possible, 
littermates of the same gender were housed in groups to reduce stress due to social isolation. 
Genotyping 
Tail and/or ear biopsies were collected digested and gDNA was extracted according to 
manufacturer’s instructions using the Genomic DNA-Isolation Kit for Tissue and Cells 
(Nexttec). Extracted DNA was diluted 1:5 in order to exclude the overload of PCR and the 
incidence of unspecific bands. Variable volumes of diluted DNA were used for different 
genotyping reactions. For PCR product visualization GelRed was added (1:20000 ratio) to each 
PCR reaction. PCR products were electrophoresed with 1.5% agarose gels in TBE buffer.  
RNA isolation and analysis  
RNA extraction:  
Frozen materials (sciatic nerves, dorsal root ganglions (DRGs) and spinal cord pieces) were 
homogenized in Trizol (Invitrogen) using the Precellyse24 homogenizer (Bertin Technologies) 
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through strong shaking for two times each for 10 s at 5500 rpm. Total RNA was extractedwith 
RNeasy® Lipid tissue Mini Kit (Qiagen) according to the manufacturer’s instructions for RNA 
extraction from lipid rich tissue.Concentration and quality (absorption ratio at 260/280 nm) of 
RNA samples were determined using the NanoDrop spectrophotometer (ThermoScientific). 
Purity and Integrity of the extracted RNA were determined with the Agilent 2100 Bioanalyser 
using the RNA 6000 Pico LabChip kit (Agilent Technologies) according to the manufacturer’s 
instructions. Total RNAs of all sample groups were stored at −80°C and were processed in 
parallel. 
RNA-seq analysis:  
Only sciatic nerve samples were used for RNA-seq analysis. Quality control, read alignment and 
differentially expressed genes: RNA-sequencing resulted in ~24 million reads per sample. 
Quality assessment was based on the raw reads using the FASTQC quality control tool (v0.10.1). 
The sequence reads (single-end 50 bp) were aligned to the rat reference genome (rn6) with 
Bowtie2 (v2.0.2)using RSEM (v1.2.29) with default parameters. First, the rat reference genome 
was indexed using the Ensembl annotations (v84.6) with rsem-prepare-reference from RSEM 
software. Next, rsem-calculate-expression was used to align the reads and quantify the gene and 
isoform abundance. The output of rsem-calculate-expression gives the read count and TPM value 
(transcripts per million) for each gene and isoform separately.  
cDNA synthesis: 
cDNA was synthesized through reverse transcription of equal amounts, 300-500 ng per reaction, 
of isolated mRNA samples, from the various tissues, was carried out. Reaction mixture consisted 
of poly-Thymin random nonamer primers (N9), oligodesoxythymidine primers (dT) as well as 
deoxynucleotide (dNTPs) and the SuperScript III reverse transcriptase (Invitrogen). 
 
Table 2: cDNA synthesis protocol 
First strand cDNA synthesis  
Reaction component volume 
RNA (~500 ng) 8 μl 
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Master mix.1: 
Oligo dT mix primer (0.6 μM) 2 μl 
N9 random nonamer primer (0.12 mM) 2 μl 
Mixture was incubated at 70°C for 2 min in order to denature all double stranded RNAs and primers. 
After wards, mixture was put on ice for short time until finishing the next step. 
Master mix. 2: 
5x 1
st
strand buffer 4 μl 
100 mM DTT 1μl 
10 mM dNTPs 2 μl 
SuperScript III reverse transcriptase (200 U / μl) 1 μl 
After adding 8 µl of master mix. 2 to each reaction mixture, the final mixture was incubated at 25°C 
for 10 min. After incubation at 50°C for 45 mins, a final incubation at 55°C for another 45 min and 
dilution of the produced cDNA to 1ng/µl was carried out. 
 
Quantitative real time polymerase chain reaction (qRT-PCR): 
 
Quantitative real-time polymerase chain reaction (qRT-PCR) was carried out using the Roche 
LC480 Detection System. The reaction mixture composed, mainly, of SYBR Green Master Mix 
(Applied Biosystems, Darmstadt, Germany), 1-2 ng of cDNA per reaction and the respective 
primers, selected with the Universal Probe Library form Roche Applied systems 
(https://www.roche-applied-science.com), of the analyzed gene. The reaction mixture was 
prepared and conducted as described in the following scheme:  
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Table 3: Pipetting scheme and program for qRT-PCR  (per reaction): 
Reaction compenent  Volume 
cDNA 2 μl  
Power SybrGreen master mix  5 μl  
Forward primer (100 μM) 0.2 μl  
Reverse primer (100 μM) 0.2 μl  
ddH2O 2.6 μl  
 
After reaction mixture preparation, it was briefly spun down and the following amplification program 
was applied:    
 
qRT-PCR program 
Step number Temperature Duration Step 
1 50°C  120 s  warm up 
2 95°C  600 s  melting 
3 60°C  20 s  annealing 
4 72°C 30 s  elongation and detection 
95°C 10 s melting back to step 3 → 45 cycles. 
4 technical replicates were prepared. 
 
For qRT-PCRs data analysis; Raw data of the qRT-PCRs were collected with Light cycler 480 
(Roche, 384 well plates) equipped via LightCycler®480 software 1.5.0SP4. Relative PCR 
products quantities (RQ), were calculated for the four technical replicates using the operating 
software. Retrieved values of each evaluated gene were normalized to the housekeeping genes 
including ribosomal protein, large, P0 (Rplp0), Peptidylprolyl isomerase A (Ppia) also know 
cyclophilin A (CypA). Averages of normalized RQ biological replicates values were depicted as 
histograms, prepared by GraphPad Prism 5, with mean RQ values in the given control group 
normalized to 100%. The Student’s t-test was used for p-value quantification.    
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Phospholipid therapy: 
Animals’ food specifications: 
Animals were fed a Standard rat chow(PS R-Z, SsniffSpezialdiäten GmbH) which is, according 
to the supplier, consisting of 35% starch, 21.2% crude protein, 6.7% crude ash, 5% sugar, 4.4% 
crude fiber and 3.8% crude fat. In order to investigate the impact of phospholipid 
supplementation on CMT1A disease progression, soy derived phospholipids mixture (Sigma, 
P3644; 55% phosphatidylcholine, 20% phosphatidylethanolamine) was mixed with the above 
described standard chow at two different concentrations, 0.3% and 3% forming what I will refer 
to as lecithin-chow in the following descriptions.  
Experimental therapy trials paradigms:  
Wild type and Pmp22-transgenic rats were fed with 3% lecithin-chow, only the long term 0.3% 
or 3%, in a multi-paradigm experimental therapy trial. Long term treatment from P2 to P112, 
early short term from P2 to P21 and early short term treatment-late effect in which the animals 
were fed with 3% lecithin-chow from P2 to P21 and then the animals were switched to normal 
food until P80. The last feeding paradigm was the late long term in which the animals received 
chow mixed with lecithin from P21 to P112. Animals were assigned randomly to each treatment 
paradigm and treatment arm. Upon reaching the end of each treatment paradigm’s termination 
time point, motor phenotyping and in vivo electrophysiological assessments were carried out. 
Motor phenotyping of controls as well as treated animals via grip strength analysis of fore and 
hind limbs. Electrophysiological assessments include nerve conduction velocity (NCV) of 
Sciatic nerve and compound muscle action potential (CMAP) of the foot intrinsic muscle of 
controls as well as treated animals. For further histological and molecular analysis, tissues were 
collected after sacrificing the animals.  
Exogenous PC incorporation into myelin sheath:  
In order to test the possibility of circulating phospholipids incorporation into the myelin sheath, 
fluorescent phosphatidylcholine BODIPY labelled TopFluor PC (Avanti polar lipids, #810281) 
was injected intravenously in wildtype animals.   500 µg BODIPY-PC dissolved in 25 µl of pure 
ethanol, were intravenously injected in the tail vein of 15 days old CMT rats. One week later, the 
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rat was sacrificed and various peripheral nerves, sciatic and tibial nerves, were collected for 
further analysis. 
Motor Phenotyping:  
Grip strength: 
Motor performance of Pmp22 overexpressing rats as well as lecithin treated  CMT1A rats  was 
evaluated via a standardized grip strength tests as described previously. For hindlimb 
measurements, the forelimbs of the animal were supported and the animal’s tail was pulled 
against a horizontal T-bar connected to a gauge. In case of forelimb measurements, the animals 
gripped the same horizontal T-bar during pulling them away from the bar with increasing force 
without any support of the hindlimbs. The recorded maximum force (measured in Newton) 
exerted by the animals, before the animal loses the grip, on the T-bar was documented and the 
mean of 8 repeated measurements was calculated.All phenotyping analyses were performed by 
the same investigator who was blinded toward genotype and treatment arms. 
Electrophysiological assessment  
Assessment of nerve conduction velocities (NCVs) and compound muscle action potentials 
(CMAPs), was carried out according to standard procedure as described previously 
139,140
. Rats 
were anesthetized via intraperitoneal injection ofmixture of Xylazine / Ketamine in order to have 
an adequate time window (20 min.) to carry out all electrophysiological recordings under deep 
anesthesia.For distal stimulation, two steel electrodes (Schuler Medizintechnik, Freiburg, 
Germany) were placed along the tibial nerve above the ankle and for proximal stimulation other 
two steel electrodes were placed next to the sciatic nerve notch. Motor recording electrodes were 
positioned in the small foot muscle of the plantar surface. Supramaximal square wave pulses 
(100ms duration) were applied using a ToenniesNeuroscreen (Jaeger, Hoechsberg, Germany). 
Compound muscle action potentials (CMAPs) were recorded after proximal and distal 
supramaximal stimulation of the sciatic and respective tibial nerve. Sciatic nerve conduction 
velocities (NCVs) were calculated using the distance between the proximal and distal stimulation 
electrodes, while the animal’s leg is completely extended, and sciatic nerve conduction latency 
measurements.  
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Muscle atrophy assessment: 
In order to assess the extent of muscle atrophy, the skin of the left forelimb was removed. The 
muscle circumference was measured by wrapping a non-sterile silk suture thread 10 times 
around the group of muscles (adjacent non overlying), attached to the radius and the ulna, 
starting from the joint toward the paw. The wrapped thread length was measured to the nearest 
millimeter using a normal desk ruler.  
Tissue preparation 
Peripheral nerve preparation: 
 
In order to collect tissues for further analysis, animals were sacrificed by cervical dislocation. 
Sciatic nerves, and in some experiments brachial plexus, DRGs and spinal cord samples were 
collected. For immunohistological investigations, sciatic nerves were fixed through immersion in 
4% PFA for 24 h at 4°C before switching them to 1% PFA for longer time fixation. Other sciatic 
nerves were cryo-embeddedin tissue tech and oriented properly to prepare longitudinal sections 
for further analysis.    
For ultrastructural evaluation, nerves were immersed in K&S-fixative (4% PFA and 2.5% 
glutaraldehyde, according to Schultz and Karlsson, 1965), for better ultrastructural evaluation, 
for at least one week before embedding them. For protein analysis or RNA profiling, various 
tissues were snap frozen using dry ice and kept at -80°C for later processing.  
Teased fiber preparation: 
 
Freshly collected sciatic nerves were transferred to a small petri dish containing PBS. The 
perineurial sheath was removed and the nerve was subdivided longitudinally into several 
fascicles which were then divided into smaller fibers bundles. Single bundles transferred to small 
single drops of PBS on a superfrost glass slide, with an adhesive surface. Using very fine 
forceps, fibers were carefully separated in order to have individual nerves fibers as much as 
possible. Slides were dried and kept at -20°C for later experimentation.  
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Light and Electron microscopy: 
After fixation for one week in K&S-fixative, nerves were fixed in 2% osmium tetraoxide which 
was followed by dehydration and embedding in epoxy resin. Semithin (0.5 μm) and ultrathin 
sections were prepared using ultramicrotome (Ultracut S ultramicrotome, Leica). 
 
For light microscopy: Semi-thin sections (0.5 μm) were prepared (Leica RM 2155, using a 
diamond knife Histo HI 4317, Diatome) and stained with a mixture of  1% toluidine blue and 
azur II–methylene blue for 1 min at 60°C. Microscopic images were collected using a 100× lens 
(Leica DMRXA), and digital images were obtained using Axiophot microscope (Zeiss) equipped 
with AxioCam MRC (Zeiss) and zen 2012 software. Counting of myelinated axons was carried 
out on whole sciatic or tibial nerve cross-sections, manually using ImageJ (NIH). 
 
For electron microscopy:  Ultrathin (50–70 nm) sciatic nerve or tibial cross-sections  were 
contrasted with 4% uranyl acetate solution for 30 min and lead citrate for 7 min (according to 
Reynolds, 1963). Electron micrographs collection was carried out with the aid of EM900 (Zeiss; 
3.500x – 30000x magnification) electron microscope which is equipped with a wide-angle dual 
speed 2K-CCD-Cameras (TRS, Moorenweis) using the Image SP software (TRS, SysProg, 
ImageSPvers. 1.1.4.62). Myelin sheath thickness comparison was carried out via calculation of 
the g ratio which is a numerical ratio between the fiber’s diameter and the diameter of the same 
fiber and the myelin sheath wrapping it. For g ratio comparison at least 150 fibers were randomly 
analyzed from each sciatic nerve at 3000X magnification. Ultrastructural analysis was performed 
by measuring the periodicity, i.e. the distance between major dense lines, for at least 20 periods 
per myelinated fiber of at least 20 myelinated fibers per sample at a 30000X magnification.  For 
all histological quantification, the experimenter was blinded with respect to genotype and 
treatment of all animals. ImagJ (ImageJ 1.48v, Wayne Rasband, National Institute of Health. 
USA; http://imagej.nih.gov/ij) was used for image analysis. 
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Embedding protocols 
Table 4: Conventional embedding of tissue in epoxy resin protocol: 
Step duration Temperature 
0.1 M Phosphate buffer (PB)  3x 10 min  4°C  
 
2% Osmium tetraoxide in 0.1 
MPB  
 
4 h 4°C 
0.1 M Phosphate buffer 3x  
 
10 min 4°C 
30% Ethanol  
 
20 min 4°C 
50% Ethanol  
 
20 min 4°C 
70% Ethanol  
 
20 min 4°C 
90% Ethanol  
 
20 min 4°C 
100% Ethanol  3x 10 min 4°C 
 
2-Propanol  
10min 4°C 
 
Propylene oxide  
 
3x 10 min RT 
2 : 1 Propylene oxide : Epon 2 h  RT 
 
1 : 1 Propylene oxide : Epon 
 
2 h  RT 
1 : 2 Propylene oxide : Epon 
 
4 h  RT 
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Immunohistochemistry 
Longitudinal sciatic nerve sections: 
In order to check whether intravenously injected fluorescent PC (Bodipy-PC) was incorporated 
into the myelin sheath during developmental myelination, longitudinal sciatic nerve sections 
(20µm) were prepared with a cryostat (Leica, Wetzlar, Germany). The sections were collected on 
glass slide and dried at RT and stored at -20°C. After hydration in PBS (0.1M)for 20min and 
fixation in 4% PFA (diluted in in 0.1M PBS), sections were washed three times with PBS (0.1M) 
and permeabilized with  triton (0.4%) dilluted PBS(0.1M) for 30 mins. Sections were blocked 
using (horse serum (4%), triton (0.2%) in PBS for 30 min. and primary antibody (anti MBP poly 
clonal rabbit (1:500; Dako)) was diluted in PBS (1x) containing HS (1%), triton (0.05 %) and 
applied overnight at 4°C. Primary antibody was washed and secondary antibody (Alexa 555 anti-
rabbit 1:500 (Invitrogen)) and DAPI, for nuclear staining, were diluted in PBS (1x)containing 
HS (1.5%) and applied at room temperature for 2 hrs. sections were washed with PBS(1x), 
immersed shortly in double distilled water, excess water was dried and slides were covered with 
aqua-polymount (Polysciences).  
 
Teased fibers staining: 
Previously teased and frozen fibers, from isolated sciatic nerves, were moved to room 
temperature and rehydrated using 1xPBS for 20 min. The slides bearing the teased fibers were 
flooded with the PBS diluted fluoromyelin (300-folds) and incubated for 20 mins at room 
temperature. Staining solution was removed and slides were rinsed with PBS 3 times for 10 min 
each.At this point teased fibers were subjected to the usual antibody staining. Prestained teased 
fibers were fixed with 4% PFA for 5 min and after washing with PBS for 3 times 5 mins each, 
they were permeabilized with ice-cold methanol for 5 mins. After washing with PBS (3X for 5 
min), blocking of the fibers with 10% horse serum and 0.1% Tween20 in PBS for 2 hours at 
pure Epon 
 
4 h  RT 
 
Transfer tissue from bucket to embedding molds and polymerize for 24 h at 60°C 
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room temperature was carried out. Then the fibers were incubated with primary antibodies 
overnightat 4°C. Slides were washed with PBS (3X for 5 min) and incubated with the respective 
secondary antibodies for 1 hour at room temperature. Finally the sildes were washed with PBS 
(3X for 5 min) and mounted with aquapolymount for microscopic examination. 
Cell culture: 
Impact of Pmp22 overexpression on PNS myelination: 
Dorsal root ganglia (DRGs) cultures were prepared by isolating DRGs from wild-type or Pmp22 
transgenic mouse embryos (C61 line, 
141
  at embryonic day 13.5 (E13.5)according to standard 
procedure
142
. Collagen coated coverslips were seeded with the trypsin dissociated DRGs at a 
density of 10 x 10
4
 cells per 1mm coverslip. After one week incubation in growth medium, 
deactivated Hyclone fetal bovine serum (10%) and NGF (50 ng/ml) in a minimal essential 
medium (MEM), for 1 week.In order to induce myelination, growth medium was supplemented 
with 50 ng/ml ascorbic acid (AA) (SIGMA) every other day until the termination time point. 
Investigated time points were 8, 10, 12 and 14 days postmyelination induction.  
 
Impact of exogenously supplied phosphatidylcholine (PC) on myelination in vitro: 
DRG neurons-Schwann cell cultures were switched to myelination medium composed of MEM 
containing 10% lipoprotein-deficient serum (LPDS) (sigma), 50 ng/ml NGF, 50ng/ml ascorbic 
acid (AA) after being incubated for 1 week in normal growth medium. Pmp22 tg  cultures grown 
on LPDS were supplemented with 2 µg/ml of L-α-phosphatidylcholine derived from Soy (PC) 
(Avanti polar lipids, #840054P), dissolved in ethanol. On the other hand, untreated cultures 
which have received equal amounts of ethanol, as in PC treated cultures, were considered as 
control cultures. Cocultures were fixed at 10 days post myelination induction for 
immunocytochemistry.   
 
Checking PC incorporated into the myelin sheath in vitro: 
At the time of myelination induction, wildtype DRG neurons-Schwann cell cultures were treated 
with 2µg/ml of TopFluor® PC (1-palmitoyl-2-(dipyrrometheneboron difluoride) undecanoyl-sn-
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glycero-3-phosphocholine; Avanti polar lipids, #810281) referred to as BODIPY-PC. On the 
hand, another set of wildtype cultures were treated with 2µg/ml of 4,4-Difluoro-5,7-Dimethyl-4-
Bora-3a,4a-Diaza-s-Indacene-3-Pentanoic Acid referred to as BODIPY (ThermoFisher, 
#D3834). Cocultures were fixed at 10 days post myelination induction for 
immunocytochemistry. 
Primary rat Schwann cells cultures: 
Schwann cells cultures were prepared from the sciatic nerves of rats at postnatal day 3 (P3) as 
described previously.() Briefly, the sciatic nerves were prepped from the newborn rats and the 
perineurium was removed. Then the nerve pieces were incubated in pre-degeneration medium 
(DMEM (Gibco) with 5% HS, 1% Pen/Strep and 2% Glutamax) overnight. Predegenerated nerve 
pieces were dissociated through incubation in a medium containing 300 µl trypsin (Gibco) & 
300µl collagenase (Gibco) for 45 mins at 37 
o
C and 5% CO2. In order to stop dissociation, horse 
serum was applied (1 ml HS (Horse Serum) + 3 ml DMEM). The resulting suspension was 
triturated, spun at 1000 rpm for 10 min. The cell pellet was then resuspended in a resting 
medium (DMEM with 5%HS, 1% Pen/Strep and 2% Glutamax), plated on a poly L lysine (PLL) 
coated plates (35 mm) and incubated overnight at 37 
o
C and 5% CO2 . In order to purify 
Schwann cell culture, cells were incubated in a selection medium (DMEM with 5%HS, 1% 
Pen/Strep, 2% Glutamax and 5 M AraC) for three days. On the third day the selection medium 
was changed to expansion medium (DMEM, 10%FCS, 10 ng/ml NRG1 (rhNRG1; Reprokine), 
4uM Forskolin (SIGMA)). Pure Schwann cells were kept for 3 days in expansion medium. 
Cultures and have been spilt when confluence was reached and cells were harvested after another 
round of growth and stored in liquid nitrogen.  
Impact of PI3K/PAkt activator on lipid biosynthesis genes in CMT Schwann cell:     
Independent Schwann cell preparation were defrosted, to be used as biological replicates, and 
cultured in resting medium (DMEM + 10% FCS) for 3 days. Afterwards, cultures were switched  
to a serum-reduced medium (1% FCS) and incubated for 1 day. Then the Schwann cells were 
harvested after being subjected to a treatment with a specific PI3K activator (740YP, Tocris) for 
6 hours and kept at -80
o
C for qRT-PCR analysis.       
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Immunocytochemistry  
Dissociated, DRG neurons-Schwann cells,cocultures were fixed (4% paraformaldehyde (PFA) in 
1x PBS for 10 min.) and permeabilized (ice-cold methanol 95% & acetone 5% mixture at -20°C 
for 4 min.). Then, the fixed cultures incubated for 1 h in blocking solution (4% horse serum, 
2%bovine serum albumin (BSA), and 0.1% porcine gelatin). Primary antibodies (poly clonal 
rabbit anti-MBP (1:400; Dako) and monoclonal mouse anti-class III β tubulin (1:500; Covance)) 
were diluted in blocking solution and applied at 4°C overnight. Coverslips were washed three 
times with 1x PBS. Then, secondary antibodies (alexa 488 donkey anti rabbit (1:400) 
(Invitrogen) and alexa 555 donkey anti mouse (1:400; Invitrogen) diluted in blocking solution 
containing 0.2 μg/ml 4′,6′-diamidino-2-phenylindole (DAPI) (Sigma), were applied and 
incubated at room temperature for 1h.  In case experiments involving treatment with Bodipy-PC 
or Bodipy, alexa 555 donkey anti rabbit (1:400; Invitrogen) and Dyelight 633 anti rat (1:500; 
YoProteins). Finally, coverslips were washed with PBS, shortly immersed in distilled water and 
mounted on slides with aqua-polymount (Polysciences).  
 
Image collection and analysis:  
Fluorescence Images were obtained with fluorescence Zeiss Axioskop microscope equipped with 
MRM camera (Zeiss). Acquisition and processing of images was carried out with Zen2 –blue 
edition (Zeiss), ImageJ (NIH), Photoshop CS (Adobe) and Illustrator 10 (Adobe) software. For 
the quantification of myelination, the total number of myelin basic protein (MBP)-positive 
myelin segments on each coverslip was counted, and statistics were done using the two-tailed 
Student’s t test. 
Myelin preparation:  
A myelin-enriched light-weight membrane fraction was purified from rats’ sciatic nerves 
homogenized in 0.27m as described previously 
143,144
. The protein concentration was measured 
by Lowry assay using DC protein assay kit (BioRAD) according to the manufacturer’s 
instructions and/or with protein gel silver staining as described previously
145
. The silver gel was 
imaged with hp Scan jet 6390C (HP intelligent scanning technology) and the density of each lane 
was measured with ImageJ (NIH).      
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Mass spectrometry: 
The amount of 1 µg of myelin membranes per sample were subjected to lipid extractions using 
an acidic Bligh&Dyer, except from plasmalogens, which were extracted under neutral conditions 
146
. Lipid standards were added prior to extractions, using a master mix containing 50 pmol 
phosphatidylcholine (13:0/13:0, 14:0/14:0, 20:0/20:0; 21:0/21:0, Avanti Polar Lipids) and 
sphingomyelin (d18:1 with N-acylated 15:0, 17:0, 25:0, semi-synthesised as described in 
147
, 200 
pmol D6-cholesterol (Cambrigde Isotope Laboratory), 25 pmol phosphatidylinositol (16:0/16:0, 
17:0/20:4, Avanti Polar Lipids), phosphatidylethanolamine and phosphatidylserine (both 
14:1/14:1, 20:1/20:1, 22:1/22:1, semi-synthesisedas described previously 
147
, diacylglycerol 
(17:0/17:0, Larodan), cholesterol ester (9:0, 19:0, 24:1, Sigma), and triacylglycerol (D5- Mix, 
LM-6000 / D5-17:0,17:1,17:1, Avanti Polar Lipids), 5 pmol ceramide and 20 pmol 
glucosylceramide (both d18:1 with N-acylated 15:0, 17:0, 25:0, semi-synthesised as described 
147
, 10 pmol phosphatidic acid (17:0/20:4, Avanti Polar) and phoshatidylglycerol (14:1/14:1, 
20:1/20:1, 22:1/22:1), semi-synthesised as described 
147
. Phosphatidylethanolamine plasmalogen 
(PE P-)-containing standard mix was supplemented with 22 pmol PE P-Mix 1 (16:0p/15:0, 
16:0p/19:0, 16:0p/25:0), 31 pmol PE P- Mix 2 (18:0p/15:0, 18:0p/19:0, 18:0p/25:0), 43 pmol PE 
P- Mix 3 (18:1p/15:0, 18:1p/19:0, 18:1p/25:0). Semi-synthesis of PE P was performed as 
described previously 
148
.  Lipid extracts were resuspended in 60 µl 10 mM ammonium acetate in 
methanol and samples were analysed in positive ion mode on an AB SCIEX QTRAP 6500+ 
mass spectrometer (Sciex, Canada) with chip-based (HD-D ESI Chip, Advion Biosciences, 
USA) electrospray infusion and ionization via a TriversaNanomate (Advion Biosciences, Ithaca, 
USA) as previously described
147,149
. Resuspended lipid extracts were diluted 1:10 in 96well 
plates (Eppendorf twintec 96, colourless, Sigma, Z651400-25A) prior to measurement. Precursor 
and neutral loss scanning was employed to measure phosphoglycerolipids and glycerolipids as 
described 
147,149
. Remaining samples were subjected to cholesterol determination as described 
150
. 
Data evaluation was done using LipidView (ABSciex) and an in house-developed software 
(ShinyLipids).  
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The lipid classes’ concentrations defined by mass spectrometric analysis were normalized to the 
measured protein concentration as assessed by standard Lowry assay (BioRad) and silver gel 
densitometry.      
Protein analysis: 
Sample preparation:  
Rats’ sciatic nerves were homogenized using  precellys24 homogenizer (bertin instruments) in 
sucrose lysis buffer (320 mM sucrose, 10 mMTris base, 1 mM NaHCO3, 1 mM MgCl2, protease 
inhibitor (cOmplete Mini, EDTA-free, Roche)). For myelin fractions analysis, samples were 
prepared according the standard procedure mentioned above. Protein concentration of the 
samples was determined by Lawry assay using RC DC™ Protein Assay biorad kit according to 
manufacturer’s instructions.  
 
Electrophoresis and Blotting:  
Protein electrophoresis was carried out using precast gradient gels (NuPAGE 4-12% Bis-Tris, 
Invitrogen). Western blots were incubated overnight with primary antibodies against p-AKT, p-
ERK, ERK (all polyclonal rabbit; 1:1,000, Cell Signaling),  polyclonal rabbit anti-PMP22 
(1:2000; Assay biotech), monoclonal mouse anti-AKT (1:1,000, Cell Signaling), and monoclonal 
mouse anti-MBP (1:1000¸ Biolegend ). Detection was performed by anti-rabbit and anti-mouse-
HRP coupled sencondary antibodies respectively (1:5000, Dianova)  and the Western Lightning 
Plus-ECL, Enhanced Chemiluminescence Substrate (Perkin Elmer) and using an luminescence 
Imager (Intas Science Imaging). For better normalization of the obtained results afterwards, 
relative protein concentration of the actual protein amount loaded two methods were used on 
different occasions. First: Coomassie staining (Imperial stain, Biorad) of the SDS gel after 
electrophoresis. Second: Total protein staining of the whole blot after the transfer step was 
carried out. 
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Statistics 
Differential expression analysis: It was carried out using gene read counts with DESeq2 
package. Genes with less than 5 reads (baseMean) were filtered out. Genes with a p-value < 0.05 
were considered to be differentially expressed. 
 
Gene ontology enrichment analysis: Gene ontology (GO) analysis was conducted using 
WebGestalt. An adjusted p-value < 0.1 using the Benjamini-Hochberg method for controlling the 
false discovery rate was set as significant for GO terms in biological processes. Results were 
confirmed using DAVID database for down-regulated genes at P18.  
Lipidomics data was analyzed using LIMMA package 
151
. Note, NA values were changed to 0. 
Linear fit was performed using lmFit function for 2 groups at P18 (Wt, Tg) and 3 groups for 
P112 (Wt, Tgpla and Tg_Tx3). For the latter, pairwise comparison was performed using 
contrasts.fit function for Wt-Tg_pla and Tg_pla-Tg_Tx3. We considered an adjusted (P18) and 
non-adjusted (P112) p-value < 0.05significant. 
 
Unless indicated otherwise, all other data was processed using MS Excel and GraphPad Prism 
v6.04. The statistical test that was used to analyze the data is indicated in the figure legends 
respectively. Briefly, for comparing two groups Student’s T-test was used, for comparing more 
than two groups one way ANOVA with appropriate post test was used and for comparing two or 
more groups for more than one time point (longitudinal analysis) two way ANOVA with 
appropriate post test was used and a p-value < 0.05 was considered significant.
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Impact of Pmp22 overexpression on CMT1A Schwann cell developmental 
transcriptional program: 
Pmp22 -overexpression leads to remarkable transcriptional dysregulation in CMT 
Schwann cells:    
The previously reported perturbation in peripheral nerves myelination in CMT1A patients as 
well as in the CMT1A animal models strongly indicates an obvious reduction in Pmp22 tg 
Schwann cell myelination efficiency
136,138
. A deeper understanding of the progressive nature of 
CMT1A disease and defining the disturbed cellular process which leads to the development of 
the characteristic demyelination neuropathy will help to define novel therapeutic approaches. 
Therefore, we have applied a multi-omics approach combining longitudinal sciatic nerve-
Schwann cell total RNA sequencing (RNA-seq) and mass spectroscopic analysis of myelin 
fractions.  
Since studying disease progression mechanisms is not amenable in humans, availability of 
reliable disease models is advantageous for such purpose. Therefore we have carried out a 
longitudinal unbiased RNA sequencing analysis of the total m RNA isolated from wildtype (Wt) 
as well as Pmp22 transgenic rat (Tg) sciatic nerves during developmental myelination starting at 
embryonic stage (E21), postnatal day 6 (P6) and ending with postnatal day18 (P18). 
Interestingly, gene ontology of the analysed regulated mRNA data set has revealed a remarkable 
disturbance of various cellular and biological processes indispensible for Schwann cell 
differentiation and myelination.  
In our attempt to group the analysed set of genes according to their patterns of regulation, we 
have categorized the genes according to expression profile similarities derived from transcript 
per million (TPM) averages values comparison over the investigated timeline. According to our 
analysis, the observed transcriptional dysregulation in CMT1A Schwann cells starts postnataly 
and become more obvious at P18 during developmental myelination. In order to get an insight 
regarding the dysregulation patterns of the global RNA transcription, we have grouped the 
individual transcripts into four distinct patterns based on expression profile similarity (Fig. 1A; 
left and middle panels).  
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Interestingly, the transcriptional levels of two major clusters of genes appeared to be remarkably 
dysregulated in Pmp22-tg Schwann cells compared to wildtype Schwann cells. Differentiation 
associated genes, in second and fourth patterns, comprise the first cluster. In the second pattern, 
one the most prominent candidates for further analysis was Schwann cell neuregulin1 type I 
(Nrg1_I) which has been proved to play a crucial role in Schwann cell redifferentiation and 
remyelination after acute nerve injury 
152
 (Fig.5A; right panel). The second cluster of genes is 
comprised of the lipid biosynthesis genes, falling in the first pattern of genes and highlighted in 
the right panel in figure1. These genes includes genes encoding the enzymes mediating lipid 
biosynthesis, metabolic, sterol biosynthesis and cellular lipid metabolic processes which fail to 
increase expression during postnatal developmental myelination when compared to wildtype 
Schwann cells (Fig5; middle panel pattern 1).    
Endogenous Schwann cell-NRG1 is continuously upregulated in Pmp22 tg Schwann cells: 
The observed subtle transcriptional upregulation of Schwann cell derived neuregulin1 type I (Sc-
Nrg1_I) in CMT1A is intriguing as it is similar to the previously reported Schwann cell Nrg1_I 
after acute nerve injury
152
. Since Schwann cell NRG1-I was shown to be only transiently 
upregulated after acute nerve injury, we wanted to examine whether upregulation in chronic 
injury is similar to that of the acute nerve injury or not. Therefore, we analyzed the 
transcriptional level of Schwann cell Nrg1_I mRNA over a timeline starting from postnatal 
developmental myelination until adulthood in a rodent model of CMT1A Tg(PMP22)C61Clh, 
termed PMP22 tg mice). In contrast to its transient upregulation in acute nerve injury, we could 
notice a continuous upregulation of Sc-Nrg1_I mRNA in CMT1A mouse sciatic nerves during 
postnatal developmental myelination (P6-P18). Such upregulation was continually increasing 
with age and could be detected early at P7 during postnatal developmental myelination until 
adulthood (P300) (Fig.6). Such remarkable NRG1 upregulation has motivated us to check 
whether it is contributing to CMT1A disease progression and disease hallmarks development. 
 
 
                                                                                                                                                             Results 
  
59 
 
 
Figure 5: Various growth and Schwann cell process are disturbed in CMT Schwann cells especially lipid metabolism 
related processes: (A) Heatmap shows the scaled TPM values (transcripts per million) for differentially expressed genes 
(adjusted p-value <0.05 and log2 fold change > |0.5|) at P18. Genes downregulated in Tg (Pmp22 transgenic) versus Wt 
(wildtype) at P18 were further divided into two patterns - genes with increasing TPM value in Wt from E21 to P18 in pattern1 
and the ones which has a plateau behavior in pattern3 as shown in (B). Likewise but in the other direction, Genes up-regulated in 
Tg vs Wt at P18 were further divided into two patterns – In pattern2 genes with increasing TPM value in Tg from E21 to P18 
were depicted and in pattern4 genes with which has shown a plateau behavior were depicted as shown in (B) also. (C) A heatmap 
is showing top ten biological process terms (from WebGestalt) for each pattern, demonstrating, among others, lipid biosysnthesis 
genes transcription is not increasing in Pmp22 transgenic rat Schwann cell as in the case of the wildtype rat Schwann cells from 
E21 to P18. Bioinformatics analysis has been carried by Prof. Stefan Bonn group (DZNE Göttingen) 
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Sc-Nrg1_I ablation in CMT1A mice could reduce hypermyelination of small to mid caliber 
axons in peripheral nerves:  
In order to determine the impact of Sc-Nrg1_I ablation in Pmp22 tg mice on the myelination 
capacity of Schwann cells, we have examined light and electron microscopic transverse sections 
of tibial and sciatic nerves (Fig.7A). On the other hand, electronmicroscopic examination of the 
myelin sheath thickness as measured by the g ratio, has revealed that there is an amelioration of 
the reported hypermyelination of small to mid-caliber axons (Fig. C) in the double mutant mice. 
Figure 6:Nrg1-I transcription is induced in sciatic nerves of CMT1A rodent models. Different behavior of 
different Nrg1 isoforms (NRG1 type I&II&III) relative mRNA transcription in different tissues: sciatic nerve 
(upper row), dorsal root ganglia (middle row) and spinal cord (bottom row) of PMP22 tg (red) compared to 
wildtype (black) mice at the age of 2, 7, 17, 79 and 300 days. Only NRG1-1 is the most significantly upregulated 
isoform over the investigated timeline (during postnatal development, myelination, and adulthood) in Pmp22-tg 
mice compared to wildtype mice. (n=3-6 per group and time point, multiple Student’s T tests).  
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Such partial amelioration of hypermyelination implies that Nrg1_I upregulation in CMT1A 
Schwann cell contributes partially to the hypermyelination in Pmp22 tg mice’s peripheral nerves.  
On the other hand, Sc-Nrg1_I ablation didn’t ameliorated the overall myelin sheath thickness as 
can be appreciated from the scatter plot of g ratios values against axons size (Fig.7B; right 
panel).                
Figure 7: Glial Nrg1-I induces hypermyelination of small to mid-caliber axons and its deletion ameliorates the pathological 
hypermyelination in PMP22 tg mice: (A) A representative electron micrographs of sciatic nerve cross sections exhibiting 
hypermyelination of small caliber axons and hypermyelination of small caliber axons in four months old PMP22 tg 
compared to wildtype mice which is ameliorated in PMP22 tg::Nrg1fl/fl::DhhCre mutants (scale bar 2.5μm). (B) Scatterplots 
of measured individual g-ratio values (averaged in B) of single fibers plotted against axon diameter shows 
hypermyelination of small to mid-caliber and hypomyelination of large caliber fibers in PMP22 tg mice compared to controls 
(Nrg1fl/fl::DhhCre, left panel). The regression line in PMP22 tg::Nrg1fl/fl::DhhCre mice compared to PMP22 tg indicates 
ameliorated hypermyelination of small to mid-caliber axons in PMP22 tg mice upon ablation of Nrg1 in Schwann cells (right 
panel). (C) Quantification of the mean myelin sheath thickness (g-ratio) in sciatic nerves from A revealed an amelioration of 
the decreased g-ratio in PMP2-tg mice after  Schwann cell Nrg1 ablation (wildtype n=5, Nrg1fl/fl::DhhCre n=5, PMP22 tg 
n=5, PMP22tg::Nrg1fl/fl::DhhCre n=5, 221-375 fibers were measured per animal, one-way ANOVA with Tukey’s post test). 
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Sc-Nrg1_I ablation in CMT1A mice didn’t rescue the reduced number of myelinated axons 
per peripheral nerve:  
In contrary, light microscopic quantification of the number of myelinated axons per sciatic nerve 
has revealed that the reduced number of myelinated axons per sciatic nerve in the double mutant 
mice (Pmp22 tg::Nrg1fl/fl::DhhCre) was not rescued (Fig.8A&B). This is in line with the 
absence of any improvement in compound muscle action potential, after Sc-Nrg1_I knockout, 
which is a read out of the amount of myelinated axons per peripheral nerve (data not shown). As 
a proof of principle, overexpression of Sc-Nrg_I in wildtype mice has led to the same 
hypermyelination phenotype of the small caliber axons which is a characteristic feature of the 
CMT1A disease (data are not shown).         
Impact of Pmp22 overexpression on lipid biosynthesis in CMT1A Schwann cell: 
Significant reduction of major lipid classes in CMT1A peripheral nerves’ myelin:  
Transcriptional downregulation of lipid biosynthesis genes in CMT1A Schwann cells has  
motivated us to check if it has an impact on the myelin lipid classes’ stoichiometery and levels in 
the myelin sheath fraction. Therefore, in collaboration with Prof. Britta Bürgger at University of 
Heidelberg, we have carried out a comparative lipidomic analysis via mass spectrometric 
analysis of myelin fraction lipid composition. 
Figure 8:Glial Nrg1-I knockout doesn’t improve the number of myelinated axons in PMP22 tg mice: (A) Representative 
light microscopic images of semi-thin cross sections from sciatic nerves of four months old wildtype, PMP22 tg and PMP22 
tg::Nrg1fl/fl::DhhCre adult mice (left panels,  scale bar 5μm). (B) Quantification of the number of myelinated axons per sciatic 
nerve cross section (right panel) is reduced in PMP22 tg (n=6) compared to wildtype (n=7) mice but not altered by ablation of 
glial Nrg1 in PMP22 tg (PMP22 tg::Nrg1fl/fl::DhhCre, n=7) when compared to single PMP22 tg mice (one-way ANOVA, 
Tukey’s post test). 
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In order to compare lipid/protein ratios of wildtype versus Pmp22 tg lipid classes amount in 
myelin fraction, measured lipid classes amounts were normalized to myelin fraction’s protein 
content. We could record a significant reduction of major lipid classes including phospholipids 
(phosphatidylcholine, phosphatidylethanolamine, phosphatidylserine, phosphatidylinositol) 
phosphatidic acid, sphingomyelin, hexylceramide and cholesterol in transgenic rats compared to 
wildtype rats. Other lipid classes, including phosphatidylglycerol, ceramide, cerebroside, 
diacylglycerol, triacylglycerol also seemed to be reduced but without reaching significance 
(Fig.9). In line, previous assessment by thin layer chromatography has revealed a remarkable 
reduction of major lipid classes in Pmp22 tg compared with wildtype myelin (Sereda etal. 
unpublished). 
 
 
Figure 9: Disturbed lipid biosynthesis is leading to disturbed lipid to protein ratio: Normalization of the measured lipid 
classes amount pre sample to the myelin fraction protein content  has revealed a significant reduction in lipid to 
protein ratios of lipid classes (PC: phosphatidylcholine, SM: sphingomyelin, PE: phosphatidylethanolamine, PS: 
phosphatidylserine, PI: phosphatidylinositol, PA: phosphatidic acid, HexCer: hexylceramide, Chol: cholesterol) in 
transgenic rats compared to wildtype rats while other lipid classes (PG: phosphatidylglycerol, Cer: ceramide, CE: 
cerebroside, DAG: diacylglycerol, TAG: triacylglycerol) showed a non significant reduction in lipid to protein ratio. Non-
adjusted p-values are shown (student Ttest). In collaboration with Prof. Britta Brügger at Heidelberg University. 
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Such remarkable reduction of phospholipids, plasmalogens and cholesterol is clearly indicative 
not only of a strong reduction of lipid biosynthesis but also a disturbed stoichiometry of myelin 
lipid composition. Therefore, we hypothesized that counteracting the consequences of Pmp22 
overexpression on lipid biosynthesis and eventually myelin sheath formation via lipid 
supplementation could be a potential therapeutic approach. This in turn has raised the question 
which lipid class or category we should supplement and in which paradigm it should be applied.  
 
In depth analysis of omics data revealed that phospholipids could be the most suitable lipid 
class for supplementation:       
In order to decide about which lipid class should be supplemented and support myelination, we 
have carried out an in-depth bioinformatics analysis combining the RNA-seq and lipidomics 
analysis results and comparing the wildtype and Pmp22 tg data sets. Interestingly, genes 
encoding the enzymes mediating the biosynthesis of the downregulated lipid classes were 
significantly reduced transcriptionally during developmental myelination especially the ones 
involved in phospholipids (Fig.10), cholesterol and glycosphingolipid biosynthesis.  
 
Among phospholipids, phosphatidylcholine is considered as a major myelin component. Hence 
combined omics analysis has revealed that its biosynthesis is severely impaired in sciatic 
nerves’s Schwann of CMT1A rats (Fig.11).  Strong downregulation of anabolic enzymes’ genes 
(CHKA: choline kinase alpha, PCYT1a & PCYT1b phosphate cytidylyltransferase 1, choline, 
alpha and beta and CHPT1: choline phosphotransferase 1) as well as catabolic enzymes’s genes 
(PLA2(PLA2G4A): phospholipase A2 group IVA and GPC-PDE (GPCPD1): 
glycerophosphocholine phosphodiesterase 1) was prominent during developmental myelination. 
This suggested that phospholipids may be best lipid class which can be used for lipid 
supplementation in CMT1A. 
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Figure 10: Gene Ontology (GO) gene sets for the 
major myelin lipid classes. Shown here are 
visualization of alterations between wildtype (Wt, 
n=4) and CMT rat (Tg, n=4) mRNA  expression in 
sciatic nerve at P18. The presented gene sets is 
for phospholipid biosynthetic process (M11978). 
The gene identifier is given to left of each color 
coded expression and bold indicates statistically 
significant regulation. In collaboration with Prof. 
Stefan Bonn, DZNE Göttingen. 
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Improvement of myelination through exogenous lipid supplementation: 
In vitro phospholipids supplementation  
Phospholipid supplementation could significantly improve myelination efficiency in in 
vitro: 
In order to test the hypothesis of phospholipids supplementation, I have evaluated, previously, 
the impact of phospholipids supplementation in vitro. Using mouse DRG cocultures, I could 
show that there is a strong reduction in the number of myelinated segments, per culture, in 
Pmp22 tg (Tg) cocultures compared to wildtype (Wt) cocultures. 
Figure 11: Choline pathway is downregulated in CMT1A Schwann cell: Downregulation in the choline metabolism pathway is 
shown as a representative pathway for the observed major downregulation of lipid biosynthesis on the transcriptomic 
(based on RNAseq data) and lipidomic (based on mass spectroscopic analysis of the myelin fraction) levels. 
Differentially expressed genes involved in choline metabolism as well as pathway intermediates in Pmp22 Tg versus 
wildtype sciatic nerves at age P18 are depicted. Choline metabolism pathway is drawn on the basis of “Choline 
metabolism in cancer” KEGG pathway. Transcriptional status of the depicted genes as well as pathway intermediates is 
explained by the different colors given and explained in the legends (blue: downregulated in transgenics compared to 
wildtype & Red: upregulated in transgenics compared to wildtype). Up and down regulated genes (adjusted p-value < 
0.05). Circles are representing the lipid products. In collaboration with Prof. Stefan Bonn, DZNE Göttingen. 
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Given the fact that these cocultures were prepared using similar numbers of cells per coverslip, 
this indeed showed that this in vitro system is recapitulating the CMT1A Schwann cell reduced 
myelination efficiency in vivo. I, then, treated Pmp22 tg as well as wildtype cocultures with 
phosphatidylcholine (2µg/ml delipidated serum medium) at the same time of myelination 
induction.Upon quantification of myelinated segments number, I have noticed a significant 
increase in the number of myelinated segments, as revealed by myelin basic protein (MBP)  
 
 
stainning, per coverslip in Pmp22 tg as well as wildtype cocultures (Fig.12). Such improvement 
is indicating the beneficial impact of phospholipid supplementation on myelination in vitro.     
Exogenous phospholipids are incorporated into myelin membrane directly in vitro and in 
vivo:        
The remarkable improvement of myelination in vitro due to exogenous lipids supplementation 
has lead us to question whether the supplemented lipids are actively incorporated into myelin 
sheath directly or it just a passive accumulation of the assimilated lipids. In order to answer this 
question, I have supplemented wildtype DRG neurons-Schwann cells cocultures with 
Figure 12:Pmp22-tg (CMT1A) Schwann cell Phosphatidylcholine supplementation improves myelination in vitro: Wild 
type (Wt) and Pmp22 transgenic (Tg) cocultures show a reduced myelination capacity in a myelination medium supplemented 
with delipidated serum. Addition of 2μg/ml phosphatidylcholine to the culture medium, supplemented with delipidated serum, 
strongly improved myelination in Wt as well as Tg cocultures. Representative images of cultures 10 days post-myelination 
induction are shown (left) as well as quantification of the number of myelin segments (left). Myelin is immunostained for MBP 
(green), neuronal fibers for TUJ1 (red). n=3-6 per group, one way ANOVA and Sidak’s multiple comparison post test, *p-value 
<0.05. 
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Phosphatidylcholine fluorescently labeled at one of fatty acid tails (Bodipy-PC) in the same 
treatment paradigm of the previous experiment. Interestingly, I could notice an evident 
colocalization of myelin specific signal, myelin basic protein (MBP) signal, and fluorescently 
labeled phosphatidylcholine (Bodipy-PC) (Fig.13A; upper panel). This is indicating that 
exogenously supplemented lipids could rescue the disturbed myelination through direct 
incorporation into myelin sheath. Upon treatment of the wildtype cultures with Bodipy, 
fluorescent head group attached to pentanoic acid, alone in the same treatment paradigm, the 
examination of the myelinated segments has revealed that there is no Bodipy signal which is 
colocalized with the myelin, MPB, signal (Fig.13A; lower panel). This, in turn, is ruling out the 
possibility that the Bodipy-PC fluorescent signal, in the previous treatment, is due a passive 
accumulation of Bodipy-PC in the myelin sheath layers.       
 
In order to check the possibility of translating the in vitro findings in vivo, I have checked the 
possibility of exogenous phosphatidylcholine incorporation in the myelin sheath when increasing 
its systemic level. Therefore, I have injected Bodipy-PC (PC; 500 μg/25µl ethanol) in the tail 
vein of wildtype rats, at postnatal day 15 (P15), during the peak of developmental myelination. 
At P22, examination of the longitudinal sciatic nerves’ section immunostained for MBP has 
revealed that there is a clear colocalization of MBP signal and Bodipy-PC (Fig.13B). Such 
colocalization is indicating that exogenously injected fluorescent phosphatidylcholine has been 
incorporated in the newly formed myelin layers formed during developmental myelination after 
injection. 
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Taken together, exogenous phospholipids active incorporation into myelin sheath in vitro and in 
vivo is implying that increasing phospholipids systemic bioavailability during developmental 
myelination may improve myelination efficiency in the peripheral nerves of CMT1A (Pmp22 tg) 
rats. Therefore, we have decided to translate the previously described findings in vivo through 
conducting an experimental therapy treatment trial to evaluate the impact of phospholipids 
supplementation therapy on peripheral nervous system myelination. 
 
 
Figure 13:Phosphatidylcholine (PC) is incorporated in the myelin internodes in vitro and in vivo: Supplemented 
fluorescent labled-PC, BODIPY-phosphatidylcholine (BODIPY-PC); 2μg/ml medium to the delipidated serum 
supplemented-myelination medium was assimilated by the myelinating Schwann cells and incorporated in the newly formed 
myelin internodes  in vitro (Upper panel in A). Control BODIPY (tagged to pentanoic acid) was not incorporated into the 
myelin membranes (lower panel in A) showing that BODIPY-PC in not passively taken up by the myelinating Schwann cells. 
Likewise, upon BODIPY-PC injection into the tail vain of a 15 days old CMT rat, i.e. during developmental myelination, 
longitudinal sciatic nerve, seven days after injection, cryo-sections have shown incorporation of BODIPY-PC into the myelin 
internodes (arrow heads) in vivo (B). (BODIPY-PC, green) and (magenta, MBP). Scale bar = 20 μm. 
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In vivo phospholipids supplementation  
Early short term (P2-P21) lecithin therapy treatment could improve myelination in 
CMT1A rat models’ peripheral nerves:  
 
In order to check whether phospholipids supplementation can promote myelination in vivo, I 
have carried out a lecithin, composed of Phosphatidylcholine, phosphatidylethalonamine and 
trace amounts of other lipids, experimental therapy treatment. In this early short term paradigm, 
we have fed Pmp22 transgenic rats with 3% lecithin enriched chow food. The treatment was 
commenced from postnatal day 2 (P2) until postnatal day 21(P21) in order to check the impact of 
the treatment on developmental myelination (Fig. 14A). Muscle strength phenotyping through 
rats’ limbs grip strength assessment, at the end of the treatment, has revealed that early short 
term lecithin therapy treatment could improve muscle strength of the Pmp22 tg rats compared 
with the non-treated transgenic group (Fig.14B; left panel). On the other hand, the lipid diet was 
well tolerated by the animals and had no effect on animals’ weight as no weight difference was 
detected after the treatment (Fig.10B; right panel). Histological, light microscopic, examination 
of tibial nerve cross sections revealed that lecithin treatment could significantly increase the 
number of myelinated axons per nerve. Quantification of the number of myelinated axons per 
tibial nerve has confirmed such significant improvement in the treated transgenic group (Fig.14 
C&D).    
 
This indicates that the treatment could enhance developmental myelination efficiency in Pmp22 
tg peripheral nerves. Electrophysiological evaluation of nerve conduction velocity (NCV) of 
sciatic nerve and compound muscle action potential (CMAP) of the foot muscle has shown no 
improvement in the treated versus untreated Pmp22 transgenic rats (data not shown).  
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Cessation of the lecithin treatment leads to lose of the beneficial effect:  
 
Since early short term treatment paradigm has been proven beneficial, I wanted to check whether 
or not the treatment impact is long lasting after treatment cessation. Therefore, I have subjected 
another rat’s cohort to the same treatment paradigm (P2-P21) and monitored the treatment 
Figure 14:Early short term phospholipid therapy ameliorates CMT neuropathy symptoms: (A)Two cohorts of CMT rats were 
fed with either normal diet or a food enriched with 3% phospholipids (PL, see methods section for detail) from postnatal day (P) 2 to 
P21 (early short term. (B) Treatment of one cohort was terminated and the cohort was analyzed at P21. Tg ctrl rats (red, n=5) showed 
a reduction in grip strength compared to Wt controls (black, n=7). Treatment with 3% PL from P2 to P21 improves grip strength in 
CMT rats (blue, n=8) (Left panel). Body weight measurement reveals no difference between the groups (right panel). One way 
ANOVA, Sidak’s post test p-value: *<0.05, **<0.01, ns: not significant. (C) Representative light microscopic images obtained from 
tibial nerve cross section at P21. Microscopic examination reveals a reduction in the number of myelinated axons in the Tg ctrl  rats 
compared to Wt rats which was partially ameliorated in the Tg treated group (Tg3% PL). (D) Quantification of the number of 
myelinated fibers per tibial nerve in the groups represented in (C) CMT rats (red, n=5) reveals less myelinated fibers compared to Wt 
controls (black, n=5). Treatment of CMT rats with 3% PL (red, n=8) significantly improves the number of myelinated fibers. One-
way ANOVA, Tukey’s post test, p-value: *<0.05, ***<0.001. Scale bar: 10μm. 
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impact afterswitching to normal food. Grip strength analysis has revealed that although the 
beneficial treatment effect was still noticeable at postnatal day 30 (P30), it has disappeared at 
latter time points; P50 and P75 (Fig.15). This indicates that lecithin treatment may be needed to 
be applied continuously to maintain the treatment beneficial effect.  
 
 
 
                
 
 
 
 
 
 
 
 
 
 
Long term (P2-P112) lecithin therapy treatment could remarkably rescue some of disease 
histological features in CMT1A rat models: 
In order to check whether lengthening the duration of the lecithin treatment will have more 
beneficial impact on myelination and disease progression of CMT1A disease in the rat model. 
Lennart Rash (MD student)  has conducted a long term treatment paradigm in which has fed the 
rats with the lecithin enriched chow food, either at 0.3% or 3% soy bean derived phospholipids, 
from postnatal day 2 (P2) to postnatal day 112(P112). In his analysis, motor phenotyping (grip 
strength), muscle circumference analysis have shown that there a remarkable improvement in 
motor in the lecithin treated CMT1A rats compared with the untreated transgenic group. In line, 
there was a significant improvement in rat’s sciatic nerve conduction velocities (NCV) as well as 
compound action potential (CMAP, unpublished). This in turn has motivated us to find out the 
histological correlates of such remarkable improvement on the level of myelination efficiency in 
peripheral nerves. 
Figure 15: Late effect of early short term 
lecithin treatment: The second cohort of treated 
(P2-P21) rats was switched to normal food and it 
motor performance was analyzed at P30, P50 and 
P75. An improvement-due to-treatment in grip 
strength is observed in Tg 3% PL (blue, n=21) at 
P30 compared to Tg ctrl (red, n=12). Such 
improvement wasn’t visible at latter time points 
P50 and P75, while both groups were weaker than 
Wt ctrl (black, n=22). One-way ANOVA, Tukey’s 
post test, pvalue: *<0.05. 
 
                                                                                                                                                             Results 
  
73 
 
Lecithin long term supplementation rescues the number of myelinated axons in peripheral 
nerves of CMT1A rodents: 
 
Light microscopic examination of the tibial nerves has revealed that there is a remarkable 
increase in the number of myelinated axons per nerve in 3% lecithin treated group compared 
with the untreated transgenic group (Fig. 16B; left panel). Furthermore, quantification of the 
number of myelinated axons per tibial nerve has revealed that there is a significant rescue of the 
number of myelinated axons per tibial nerve of 3% lecithin treated Pmp22 transgenic rats group 
to an extent reaching the wildtype level (Fig. 126; right panel). In order to evaluate the impact 
of long term treatment paradigm on the myelin morphology characteristics including myelin 
sheath thickness and myelin ultrastructure. 
 
Examination of electron micrographs of the tibial nerve cross sections, carried out by Lennart 
Rasch, has revealed that the treatment couldn’t rescue the disturbed myelination phenotype 
characteristic for CMT neuropathy. The treatment couldn’t rescue the hypermyelination of the 
small to mid-caliber axons and the hypomyelination of the large caliber axons. Precise 
quantification of the myelin sheath thicknesses relative to the corresponding axons’ calibers, i.e.: 
g ratio, has revealed that the g ratio of the 3% lecithin treated transgenic group was even lower 
than the already reduced g ratio of  untreated transgenic control group . This is indicating an 
increase in hypermyelinated axons per tibial nerve. These observations could be even more 
obvious when the g ratio data was plotted against the axons caliber as the treatment did not 
change the steepness degree of the regression line of the Pmp22 tg g ratio in case of the 3% 
lecithin treated transgenic group.  
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Lecithin long term supplementation rescue the mild widening of myelin sheath lamellae in 
peripheral nerves of CMT1A rodents: 
 
The previously reported widening of myelin interperiodic distance observed in Pmp22 tg 
myelinating cocultures of DRG neurons-Schwann cells
153
 has motivated us to check whether this 
phenotype is present in vivo. Analysis of Pmp22 transgenic myelin sheath ultrastructure in highly 
magnified electron micrographs (80000x) has revealed that there is a mild, but significant, 
widening of the interperiodic distances compared to the wildtype ones (Fig. 17A). Interestingly, 
quantification of the interperiodic distances in the myelin sheath of 3% lecithin treated Pmp22 tg 
rats has shown a remarkable rescue of the above described widening of the distance between 
myelin lamellae reaching the wildtype level (Fig. 13B).         
Figure 16:Improved motor phenotype and electrophysiological aspects due to long term phospholipid therapy are coinciding 
with improved number of myelinated axons per peripheral nerve : (A) Treatment scheme. CMT rats (Tg) as well as wildtype 
rats (Wt) where fed with either normal diet, or a food enriched with 0.3% or 3% phospholipids (PL) from postnatal day (P) 2 to 
P112. (B) Representative images of tibial nerve’s semi-thin cross sections (left panel) of Wt ctrl (left), Tg ctrl (middle) and Tg 3% 
PL (right) are showing a reduced myelinated fiberes density in Tg ctrl compared to Wt ctrl, which is remarkably ameliorated in Tg 
3% PL. Scale bar: 10μm. Quantification of the number of myelinted fibers per tibial nerve’s cross sections (right panel) is reveling 
an increased number of myelinated fibers, at P112, in case of 3% PL, but not in case of 0,3% PL treatment (Wt ctrl, black, n=9; Wt 
3% PL, grey, n=9; Tg ctrl, red, n=13; Tg 0.3% PL, purple, n=7; Tg 3% PL, blue, n=10). One-way ANOVA, Tukey’s post test, p-
value *<0.05.  
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Lecithin treatment couldn’t rescue the disturbed myelin morphology in CMT1A rat model:  
 
In our quest to try to find a histological correlate which may explain the slightly improved nerve 
conduction velocity, we conducted a deeper myelin morphology analysis. Therefore, I have 
prepared teased fibers specimens from the sciatic nerves of the wildtype (Wt), Pmp22 tg ctrl (Tg 
ctrl) and 3% lecithin treated Pmp22 tg  (Tg 3% PL) rats. Fluoromyelin staining, a stain which is 
absorbed preferably by the lipid enriched membranes, of the myelin sheath in the teased fibers 
samples has enabled myelin intermodal length determination. Analysis of the intermodal length 
measurements has revealed that there is a striking reduction in the intermodal length of Tg ctrl 
rats’ peripheral nerves compared with Wt ctrl. Such reduction couldn’t be rescued in the 
3%lecithin treated transgenic rats (Tg 3% PL). This can be readily perceived from intermodal 
length averages comparison (Fig. 18A) as well as the relative frequency distribution of the 
measured intermodal length (Fig. 18B). 
 
Figure 17:Long term phospholipid therapy improves myelin lamellae periodicity in CMT1A rats: (A) Increased 
myelin periodicity in CMT (Tg ctrl) rats compared with wildtype (Wt) rats. Representative electron micrographs of tibial 
nerves cross sections of Wt and Tg at 30000x magnification; scale bar: 50 nm. In the representative electron micrographs, 
30 consecutive major dense lines are marked with white ticks in Wt and well as Tg micrographs. The ticks are spanning 
longer distance on the Tg side compared with Wt side indicating an increased periodicity in Tg. (B) Ameliorated myelin 
periodicity in CMT rats after PL treatment. Interperiodic distance quantification of Wt, Tg as well as Tg 3% PL (P2-
P112) rats (n=4 per group, one way ANOVA, Holm-Sidak’s multiple comparison post test). A minimum of 20 periods 
per fiber in at least 20 fibers per animal were measured. 
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Since the nodes of Ranvier are characterized by enrichment of sodium channels, Nav1.6 subtype, 
I have made use if that in order to measure the nodal length. Analysis of immuno-
histochemically stained teased fibers samples for Nav1.6 has revealed that there is a significant 
increase in the nodal length in Tg ctrls compared to Wt ctrls. Such nodal length increase couldn’t 
be rescued in 3% lecithin treated group (Tg 3% PL) (Fig.18C).     
 
Figure 18:long term phospholipid therapy had no impact on myelin morphology: (A) Myelin sheath internodal length 
measured in teased fibers, of wildtype (Wt ctrl)& Pmp22 tg (Tg ctrl) and 3% lecithin treated Pmp22 tg (Tg 3% PL), samples 
prepared from sciatic nerves revealed that long term treatment couldn’t rescue the reduced intermodal length in Pmp22 tg (Tg 
ctrl). (B) Relative frequency distribution of intermodal length measurements presented in A showing that the 3% lecithin 
treatment couldn’t rescue the shift in Tg ctrl intermodal length relative to wildtype. (Wt ctrl, black, n=5; Tg ctrl, red, n=5; Tg 3% 
PL, light blue or gray, n=5). One-way ANOVA, Tukey’s post test, p-value ***<0.0001. (C) Nodal length comparison derived 
from sodium channel (Na v 1.6) staining is showing a significant increase in nodal length on Tg ctrl compared to Wt ctrl which 
was rescued in Tg 3% PL. (Wt ctrl, black, n=4; Tg ctrl, red, n=3; Tg 3% PL, light blue, n=3). One-way ANOVA, Tukey’s post 
test, p-value *<0.05. Schmidt Lantermann incisures analysis derived from teased fibers stained for myelin associated 
glycoprotein (MAG) revealed that there is no improvement in Tg ctrl group’s reduced SLI length (D), pathologically increased 
SLI (E) and total SLI length per intermodal length (F) in the 3% Tg PL group. (Wt ctrl, black, n=5; Tg ctrl, red, n=5; Tg 3% PL, 
light blue or gray, n=5). One-way ANOVA, Tukey’s post test, p-value **<0.001,  ***<0.0001.             
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Schmidt Lantermann incisures (SLIs) which is a myelin unique morphological structure, in the 
peripheral nervous system, is characterized by the abundance of specific proteins including 
myelin associated glycoprotein (MAG). Quantification of SLI number per myelin internode has 
shown that there is a significant increase in the number of SLIs in CMT1A rats’ peripheral 
nerves compared with wildtype peripheral nerve. However, the long term treatment couldn’t 
reduce the number of SLIs per peripheral nerve transgenic treated rats (Tg 3% PL) (Fig.18D). 
Moreover, the treatment couldn’t rescue the reduction in the single SLI length (Fig.18E) and the 
increased total sum SLIs length relative to intermodal length in the Tg ctrl group (Fig.18F).          
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Impact of dietary phospholipids supplementation on myelin lipid as well as protein 
composition:   
Impact on myelin lipid composition:     
 
Myelin fraction mass spectrometric analysis of wildtype and Pmp22 tg rats’ sciatic nerve at P18 
has revealed that there is an obvious reduction of all the major lipid classes (Fig. 9). Therefore, I 
examined whether lipid treatment could rescue that reduction. In order to achieve that, we have 
prepared sciatic nerve myelin fraction of wildtype, Pmp22 tg and 3% lecithin treated Pmp22 tg at 
P112 and subjected them to lipid classes mass spectrometric analysis in collaboration with 
Prof.Britta Brügger at Heidelberg University. Although stoichiometry of the major lipid classes 
appeared to be barely altered in CMT1A rat’s myelin fraction compared to wildtypes’; only two 
lipid classes were the mostly disturbed. A relatively significant reduction in 
phosphatidylethanolamine (plasmalogen) was detected in CMT1A rat’s sciatic nerves control 
which couldn’t be rescued by lecithin treatment. The triacylglycerols lipid class was relatively 
increased in control Pmp22 tg rats as well as treated Pmp22 tg rats compared to wildtypes 
(Fig.19A).            
 
 
In order to check whether the lecithin treatment could improve the lipid to protein ratio in myelin 
fraction, we have normalized the lipid classes measured values to the protein content of the 
myelin fraction. Normalized Lipid classes’ values comparison of wildtype (Wt) as well as 
untreated (Tg ctrl) and treated transgenic (Tg 3% PL) rats has revealed that there is a remarkable 
significant reduction in almost all lipid classes in CMT1A rat myelin. More importantly, lipid to 
protein ratios in treated CMT1A rats showed obvious trends towards normalization, although the 
majority of individual lipid classes’ did not reach significance when compared with non-treated 
CMT1A controls (Fig.19B). It is noteworthy that there the observed high variability may be is 
resulting from the disease severity variability of the animals within the same group which in turn 
may explain the lack of significance despite the obvious trends towards normalization.     
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Impact on myelin lipid fatty acid chains: 
Another evidence for exogenously supplemented lipids incorporation into myelin sheath could 
be concluded from analyzing the acyl carbon chain length which is most likely abundant in 
phospholipids with two C18 acyl chains. Acyl carbon chain analysis has shown that acyl carbon 
chain 36 percentage is less abundant in CMT1A rats myelin lipids but was rescued after lecithin 
treatment. In addition, the percentage of 54 acyl carbons (most likely TAGs with three C18 acyl 
chains) is increased in CMT rats but again reduced after PL treatment (Fig.19C). It is noteworthy 
that the majority of the supplemented phospholipid species contained a total of 36 acyl carbons 
in two fatty acid residues and the lecithin enriched diet was comprised of 85% 18-carbon fatty 
acids. Therefore, increase of 36 acyl carbon lipids after PL therapy suggests that dietary lipids 
have been incorporated into the myelin sheath.     
 
Impact on myelin lipid biosynthesis genes transcription:  
 
In order to check whether a rescue of the lipid biosynthesis genes’ transcription is underlying the 
observed amelioration trend of lipid classes’ levels in myelin sheath, we have evaluated the 
transcriptional levels of major lipid biosynthesis enzymes.        Surprisingly, qRT-PCR analysis 
of sciatic nerve mRNA revealed no improvement of the transcriptional down-regulation of lipid 
genes including 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase (Hmgcr), fatty acid 
synthase (Fasn) and choline kinase alpha (Chka) genes  in Pmp22 tg rats after 3% lecithin 
treatment (Fig.20). 
 
Impact on myelin’s protein content:  
 
As cellular proteins translocation is mediated by lipids, we were interested to know if improving 
cellular lipids will improve myelin proteins translocation. Therefore, we have carried out a 
Western blot analysis of the myelin fraction as well as whole nerve lysate isolated the treated 
Pmp22 tg rats as well as wildtype and untreated transgenic controls. 
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Figure 19:Dietary phospholipid improved myelin’s lipid/protein ratio in CMT1A rat model: (A) Mass 
spectrometric analysis, in collaboration with Prof. Britte Brügger (Heidelberg University), of sciatic nerve myelin 
from Wt ctrl (black, n=4), Tg ctrl (red, n=3) and Tg 3% PL (blue, n=3) rats, purified after study end (P112), 
normalized to total lipid content in the samples, shows widely unaltered stoichiometry (mol %) between Wt, Tg ctrl 
and Tg PL, except for lower PEP and higher TAG in CMT rats compared to Wt. Adjusted p-values are shown (two-
way ANOVA). (B) Normalized lipid classes concentration, in sciatic nerve myelin shown in (A), to myelin protein 
shows a reduction in many lipid classes in Tg ctrl rats compared to Wt ctrl rats. Despite the observed trend toward 
increasing lipid classes levels, PL treatment did not significantly improve lipid to protein ratios in purified myelin.  
Chol: cholesterol, PC: phosphatidylcholine, PE: phosphatidylethanolamine, PEP: PE plasmalogens, PS: 
phosphatidylserine, PI: phosphatidylinositol, PA: phosphatidic acid, PG: phosphatidylglycerol, SM: sphingomyelin, 
HexCer: hexylceramide, Cer: ceramide, SGalCer: S-galactosylceramide, CE: cerebroside, DAG: diacylglycerol, 
TAG: triacylglycerol. Non-adjusted p-values are shown (One way ANOVA). (C) Mass spectrometric analysis of 
sciatic nerve myelin with respect to the fatty acid chain length abundance displaying the  number of acyl carbons per 
lipid molecule as mol percent per sample (only species >1 mol%). Note that 36 acyl carbon molecules are less 
abundant in CMT compared  to Wt rat myelin and is normalized after PL therapy, suggesting that the  supplemented 
phospholipids (mostly comprised of C18 fatty acids, see methods) have reached the myelin sheath.  
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Western blot analysis has revealed that there was no major differences in protein content 
between peripheral myelin protein 22 (PMP22) and myelin protein zero (MPZ) in untreated and 
Lecithin (PL) treated CMT rats, and when compared to wildtype controls (Fig.21; B left panel 
&C right panel). 
 
Interestingly, Myelin Basic protein (MBP) level was slightly increased in myelin after lecithin 
therapy in CMT rats, but remained unaltered in full nerve lysates (Fig.21; B right panel & E). 
Interestingly, upon comparing the relative levels of PMP22 to MBP in the myelin, we could see 
amelioration of the perturbed ratio in CMT rats’ myelin fraction reaching the wildtype level 
(Fig.21; C left panel).    
 
Impact of dietary long term phospholipids supplementation on Schwann cell 
differentiation: 
Alleviating CMT1A disease progression on functional, histological levels and myelin lipid 
composition has motivated us to examine whether such improvements were due to improved 
Schwann cell differentiation and downstream signaling pathways. Therefore, I have carried out a 
western plot analysis, using the whole nerve lysate, of the two major Schwann cell differentiation 
and dedifferentiation pathways; PI3K/AKT and MEK/ERK. Signaling pathway activation  
 
Figure 20:Dietary phospholipids treatments couldn’t induce lipid biosynthesis genes transcription: qRT-PCR of 
P21 sciatic nerve mRNA from treated CMT rats (early short term) shows no improvement of the transcriptionally 
downregulated lipid genes like Hmgcr, Fasn, Chka, while an improvement of pla2g4a is obvious in Tg rats after 3% PL 
treatment (P2-P21, n=8 per group, one way ANOVA). 
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Figure 21:Dietary phospholipid couldn’t rescue myelin’s protein content in CMT1A rat model: (A) Western blot analysis of PMP22, 
MBP and MPZ in purified P112 sciatic nerve’s myelin fraction isolated from wildtype control (Wt ctrl) , Pmp22 tg control (Tg ctrl) and 
3% lecithin treated Pmp22 tg (Tg 3% PL) rats. As loading control, a coomassie staining of the gel was performed (n=3 per group). Shown 
is the coomassie gel for the PMP22 and MBP blot. MPZ was analyzed on a second blot (coomassie gel not shown). (B) Quantification of A 
(first and third panel) shows that there is an increased PMP22 concentration, normalized to coomassie, in CMT1A rat myelin fraction and 
no reduction has been observed in 3% lecithin (Tg 3%PL) treated transgenic rats (left panel). On the other hand, an obvious reduction of 
myelin MBP, normalized to coomassie, has been observed in CMT1A (Tg ctrl) rats but a significant partial rescue, increase, in case of 3% 
lecithin (Tg 3%PL) treated transgenic rats has observed (right panel, student’s T test). (C) An increased PMP22 / MBP ratio in myelin of 
Tg compared to Wt controls (left panel, one way ANOVA). Quantification of A (second panel) has revealed that there is no rescue of the 
reduced myelin MPZ concentration in CMT1A myelin fraction in 3% lecithin treated transgenic (Tg 3%PL) rats compared to CMT1A 
control rats (Tg ctrl). (D) a Western blot analysis of MBP from P112 sciatic nerve full protein preparations from Wt, Tg ctrl and Tg 3% PL 
treated (P2-P112) treated rats. As loading control, a coomassie staining of the gel was performed (n=3 per group, left panel). (E) 
Quantification of D shows decreased MBP abundance in Tg compared to Wt nerves). In non-treated (Tg ctrl) versus treated (Tg 3%PL) 
CMT rats, no quantitative difference of MBP abundance could be detected, when normalized to Coomassie (n=3 per group, One way 
ANOVA with Tukey’s post test). 
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determination through phosphorylation extent evaluation has revealed that lecithin treatment 
couldn’t rescue the downregulated PI3K/AKT activity in CMT Schwann cells at early, postnatal, 
stage P21 (Fig.22A). Likewise, the treatment couldn’t reduce the pathologically upregulated 
MEK/ERK pathway in CMT Schwann cell at later, adulthood, stage P112 (Fig.22B). In line, 
transcriptional evaluation of major differentiation transcription factors, including early growth 
response 2(Egr2); also known as Krox-20, POU domain class 3 transcription factor 1 (Pou3f1); 
also known as Oct-6, myelin protein zero (Mpz), myelin basic protein (Mbp) has revealed that 
the treatment couldn’t rescue their disease related significant reduction. Moreover, the treatment 
couldn’t reduce the pathological upregulation of the dedifferentiation transcription factors as the 
in the case of c-Jun (Fig.22C). Interestingly, when we treated primary Schwann cells purified 
from CMT rats with a cell permeable PI 3-kinase (PI3K) activator, we could detect a significant 
increase in mRNA transcription of major lipid biosynthesis genes including Hmgcr, Fasn and 
Chka (Fig.22D). 
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Figure 22:Dietary phospholipids supplementation couldn’t rescue the perturbed CMT1A Schwann cell differentiation: (A)  
Western blot analysis with full nerve lysates from Wt, Tg ctrl and Tg 3%PL (P2- P21) treated rats was performed at P21 and shows less 
AKT activity in Tg rats as measured by phosphorylated AKT over constitutive AKT. No alteration was revealed after PL treatment. 
Quantification is shown in the right panel (n=3 per group, one way ANOVA). (B) Western blot analyses with full sciatic nerve lysates 
from P112 Wt ctrl, Tg ctrl and Tg 3%PL (P2.P112) rats shows no amelioration of the increased ERK activity in CMT rats after PL 
treatment, as assessed by ERK phosphorylation over constitutive ERK. Quantification is shown in the right panel (n=3 per group, One way 
ANOVA with Tukey’s post test.). (C) qRT-PCR analysis with sciatic nerve mRNA extracts of P112 wildtype rats (wt), non treated CMT 
rats (tg ctrl) and CMT rats treated from P2-P112 with 3% PL. No treatment effect can be detected for the differentiation markers Egr2, 
Pou3f1, Mpz, Mbp and the dedifferentiation marker cJun (n=8 per group, One way ANOVA with Tukey’s post test.). (D) Treatment of 
purified primary Schwann cells from CMT rats with a specific PI3K activator (740YP) resulted in an increased mRNA expression of the 
lipid genes Hmgcr, Fasn and Chka, as assessed by qPCR 6h after treatment began (n=6 per group, student’s T test). 
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Pmp22 duplication in the Schwann cell during postnatal developmental myelination leads to 
slowly progressive demyelination and axonal loss in adult peripheral nerves which are 
characteristics for Charcot-Marie-Tooth Disease 1A (CMT1A). Relying on human patients’ 
samples for understating progression of CMT1A is difficult due to tissue in availability. 
Therefore, the availability of reliable CMT1A rodent models is advantageous.  We have used 
two rodent models for understanding CMT1A disease progression as well as experimental 
therapy trials. CMT Schwann cell timeline RNA-seq analysis, during developmental myelination 
(E21-P18), has revealed a remarkable overexpression of Schwann cell NRG1 in CMT sciatic 
nerves of the rat model. Interestingly, validation of such noticed upregulation with real time PCR 
has revealed that it is continuously upregulated over the investigated timeline from early 
postnatal days until adulthood in both rat and mouse models.         
 
The observed continuous upregulation of Schwann cell NRG1_I is a remarkable response to the 
chronic overexpression in CMT Schwann cell in particular when compared to the transient 
upregulation in the case of acute nerve injury
152
.  In contrast to the beneficial impact of the 
transient Sc-NRG1_I upregulation on Schwann cell remyelination after acute nerve injury
152
, 
Schwann cell continuous upregulation of NRG1_I has detrimental effects on developmental 
myelination. We could demonstrate that through the double Sc-NRG1_I knockout and PMP22 
overexpressing mice which has led to an amelioration of the characteristic CMT 
hypermyelination of the small caliber axons in the peripheral nerves. Indeed, this finding is 
clearly indicative that continuous Sc-NRG1_I upregulation is contributing, via Schwann cell 
NRG1_I paracrine/autocrine stimulation in addition to normal axonal NRG1_III stimulation, to 
the small caliber axons hypermyelination observed in CMT1A animal models
138
 which leads 
eventually to motor deficits.    
 
In contrast to the transient upregulation of Sc-NRG1_I in wildtype, denervated, Schwann cells in 
response to acute nerve injury
152
, Sc-NRG1_I is contentiously over expressed in CMT Schwann 
cells which still in contact with axons. Therefore, we suggest that such continuous upregulation 
of Sc-NRG1_I is due to ongoing rounds of de and remyelination in adulthood as has been 
reported in peripheral nerves of various demyelinating neuropatheis
65
. In contrast to Schwann 
cells remyelinating mature axons with low level of NRG1 expression in case of CMT, higher 
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levels of axonal neuregulin (NRG1_III) are evident during developmental myelination. 
Therefore, the difference in Sc-NRG1_I expression onset and level may set the grounds for 
explaining the observed perturnbed Schwann cell response in case of CMT1A demyelinating 
neuropathy.      
 
Another striking observation which we learned from the timeline RNA-seq analysis is that lipid 
biosynthesis genes are strongly downregulated. This is in line with the previously concluded 
persistent transcriptional downregulation of lipid biosynthesis genes in the same animal model at 
P7 and P63 compared to wildtype Schwann cells
140
. In line, we have shown a strong reduction in 
all major myelin lipid classes including cholesterol, phospholipids and plasmalogens. Both 
findings demonstrate a defective lipid biosynthesis machinery in CMT Schwann cell which may 
explain the delayed onset of myelination and perturbed myelin sheath ultrastructure including 
intermodal length, thickness and compaction. Such reduced Schwann lipid biosynthesis 
efficiency due to transcriptional downregulation of lipid biosynthesis genes is in agreement with 
the previously reported downregulation of PI3K/Akt/mTOR signaling pathway activity
138
which 
controls lipid biosynthesis in the Schwann cell 
22,154
 . We could experimentally address such 
hypothetical link by using a specific activator of AKT in order to stimulate PI3K/AKT pathway 
in Pmp22 tg Schwann cell in vitro. Indeed, enhanced PI3K/AKT pathway activity has could 
improve lipid biosynthesis genes transcriptional levels. Taken together, the enumerated 
observations are indicating that lipid biosynthesis is a result of the PI3K/AKT pathway, major 
Schwann cell differentiation pathway, downregulation.  
 
As a result, the previously described slowed and hence prolonged myelination in CMT1A 
138
, 
together with ongoing de- and remyelination in adult disease stages require a continuous lipid 
biosynthesis by Pmp22 transgenic Schwann cells, next to physiological myelin turnover. In 
addition, fluorescent phospholipid molecules tracing has revealed that they are actively 
incorporated in to the myelin sheath in vitro as well as in vivo. Such observation has been also 
described in pulse chase experiments in which intraperitoneal application of phospholipid 
precursors could be rapidly taken up by Schwann cells and incorporated into myelin
155
. Taken 
together, these observations are indicating that the myelin sheath is highly plastic and its lipid 
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composition improvement is amenable via improving Schwann cell lipid biosynthesis and/or 
exogenous lipids availability.   
 
In light of the abovementioned findings and in accordance with previous successful attempts of 
treating lipid biosynthesis deficiency related disorders, we hypothesized that increasing lipids 
availability may improve myelin sheath formation by CMT Schwann cells. To our interest, we 
could recapitulate the reduced myelination efficiency of CMT Schwann cell
138
 in vitro. In line 
with previous reports 
126
, we could notice a significant reduction in the CMT Schwann cell 
myelination efficiency in DRG neurons-Schwann cells cocultures compared to wildtype cultures. 
More importantly, treatment of transgenic as well as wildtype cocultures could enhance 
myelination efficiently. Furthermore, translating this finding in vivo using a CMT1A rat model 
through feeding the animals with phospholipids, lecithin, enriched chow food has led to a 
remarkable improvement on the functional (muscle strength), electrophysiological (NCV and/or 
CMAP) and histological (number of myelinated axons) level.  
 
Although the various lecithin treatment paradigms have alleviated CMT1A disease progression 
with different extents, it is not worthy that cessation of lecithin treatment after the early short 
term paradigm has resulted in a treatment effect loss. This can be explained by the persistent 
defect of Schwann cell differentiation and the reduced PI3K/AKT signaling which leads to 
transcriptional downregulation of lipid biosynthesis. Such assumption was evident upon 
evaluation of lipid biosynthesis genes transcriptional levels in CMT Schwann cells at adulthood 
time points. In line, comparison of the various paradigms outcomes has revealed that the long 
term treatment was the most efficient treatment paradigm in alleviating CMT1A disease 
progression which indicate the continues need for the lipid supplementation.  
 
Importantly, commencing the treatment at later stages, as concluded from other parallel therapy 
trial carried out by Dipl. biol. Jan Stenzel from our group (late long term paradigm) has exerted 
noticeable therapeutic impact on CMT1A in the rat model. This observation is of valuable 
clinical relevance as it opens the possibility for translating thesis findings into clinical trials with 
patients affected by CMT1A disease as most of the patients seek medical help during the second 
decade of life 
129
. In addition, the fact that CMT1A is a disease with a variable severity, 
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commencing the treatment at adult stages, symptomatic patients, can be adapted to the degree of 
severity which in turn help avoiding overtreatment and side effects in pediatric patients. In 
addition to the possible treatment adaptability, dietary phospholipids have been used in many 
clinical trials and had no substantial side effects
156
. Other phospholipid treatments has been 
associated with low cardiovascular risk, antiinflammatory effects in rheumatoid arthritis and a 
potential positive influence on memory and cognition in neurological disorders
156
. 
 
Taken together, the outcomes of the various lecithin treatment paradigms are indicate that 
commencing the treatment at later stages still proved to be beneficial. It could improve 
electrophysiological, functional and histological aspects of the peripheral nerves of Pmp22 tg 
rats but to a lesser extent compared to the outcomes of the long term treatment which has been 
commenced at the beginning of the postnatal developmental myelination. On the other hand, the 
outcomes of the late long term treatment have shown that it is a bit better than the early short 
term treatment paradigm outcomes but again less than the early long term treatment impact.  
 
Therefore, we concluded that the long term lecithin treatment starting at the beginning of the 
postnatal developmental myelination until adulthood is the most effective phospholipid 
supplementation paradigm in alleviating CMT1A like symptoms in the rat model.                              
 
Analysis of myelin ultrastructure has revealed that there a widening of the interperiodic distances 
between myelin layers in the myelin sheath of the tg animals compared to wildtype. Such 
interperiodic distances widening has been described in the peripheral nerve biopsies isolated 
from CMT1A patients as well as DRG-neuron Schwann cell cocultures
153
. Interestingly, lecithin 
treatment has resulted in restoration of normal interperiodic distances in the peripheral nerves’ 
myelin sheath of CMT1A treated rats. Since myelin stoichiometry hasn’t been affected 
dramatically in CMT rat’s peripheral nerves, it can’t explain the observed widening. On the 
other, the remarkable improvement in lipid classes, normalized to myelin protein content, in the 
lecithin treated CMT1A rats’ myelin fraction can explain the normalized myelin lamellae 
periodicity. In line, it has been recently described that ablation of fatty acid or plasmalogen 
phospholipids synthesis has led to a widened myelin periodicity 
157,158
which indicate that 
improved myelin lipid content can improve periodicity . 
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In summary, we have described a continuous upregulation of Schwann cell NRG1_I in CMT1A 
which we could show that it is underlying the observed hypermyelination of the small caliber 
axons in the peripheral nerves. In addition, we have identified a pronounced lipid biosynthesis 
downregulation in CMT1A Schwann cell which is consequence of the reduced 
PI3K/AKT/mTOR pathway axis activity. Dietary phospholipids supplementation in order to 
overcome the reduced endogenous CMT1A Schwann cell lipid biosynthesis has led to improved 
myelination efficiency. In turn, phospholipid treatment has improved myelin lipid composition, 
ultrastructure and number of myelinated axons per peripheral nerve which indeed had improved 
motor function. In summary, the improved myelin biosynthesis and the CMT1A clinical 
phenotype amelioration in the CMT1A rats show that dietary lipid supplementation may 
constitute a potential translatable therapeutic approach for CMT1A disease. 
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Appendix A: Abbreviation list: 
Abb. Meaning 
AKT Protein Kinase B 
AP1 Activator protein 1 
Arf6 ADP ribosylation factor-6  
CHKA choline kinase alpha 
CHPT1 choline phosphotransferase 1 
CMAP Compound muscle action potential  
CMT Charcot-Marie-Tooth  
CMTA1 Charcot-Marie-Tooth A1  
CNS Central nervous system 
CypA) cyclophilin A  
DLg1 Discs large homolog 1  
DRG dorsal root ganglions  
EAE experimental autoimmune encephalomyelitis  
Egr2 Early growth response protein 2 
ER Endoplasmic Reticulum  
ErbB2/ErbB3 Erythroblastic leukemia viral oncogene homolog 2/3 
Erk1/2  extracellular signal–regulated kinases 
GPC-PDE (GPCPD1) glycerophosphocholine phosphodiesterase 1 
HDAC1 Histone deacetylase 1 
HDAC2 Histone deacetylase 2 
HNPP hereditary neuropathy with liability to pressure palsies  
Id2 inhibitor of DNA binding-2  
Id4 inhibitor of DNA binding-4 
Krox20 ERG2 gene encoding Early growth response protein 2 
LDLR low density lipoprotein receptor  
Lpin 1 phosphatidate phosphatase gene 
MAG myelin-associated glycoprotein  
MBP myelin basic protein  
MEK Mitogen activated kinase 
MPZ Myelin Protein Zero 
mTOR mammalina Target of Rapamycin  
NAB NGFI-A/Egr-binding 
NCV nerve conduction velocity  
NFATc4 calcineurin-dependent-4  
NFATc4  Nuclear Factor Of Activated T Cells 4 
NF-kB nuclear factor 'kappa-light-chain-enhancer' of activated B-cells 
NGF Neuronal growth factor 
NICD Notch intracellular domain 
                                                                                                                       Appendices 
107 
 
NRG 1_I Neuregulin 1 type I 
NRG 1_III Neuregulin 1 type III 
Oct 6.  octamer-binding transcription factor-6 
OL oligodendrocyte 
PA phosphatidic acid  
PCYT1a/b phosphate cytidylyltransferase 1 choline, alpha and beta  
PFA Paraformaldehyde  
PI3K phosphatidylinositol 3-kinase 
PIP2 Phosphatidylinositol 4,5-bisphosphate 
PIP3 Phosphatidylinositol (3,4,5)-triphosphate  
PLA2(PLA2G4A phospholipase A2 group IVA  
PLC Phosopholipase C 
PLP proteolipid protein  
PMP22 Peripheral Myelin Protein 22 
PNS Peripheral nervous system 
Ppia Peptidylprolyl isomerase A  
PTEN Phosphatase and Tensin homolog 
QPCR Quantitative real-time polymerase chain reaction  
SC Schwann cells 
SCAP SREBP cleavage-activating protein  
SCP Schwann cell precursors  
SHP2 Src homology region 2-containing protein tyrosine phosphatase 2 
SLIs Schmidt Lantermann incisures  
Sox10 SRY-related HMGbox- 10  
SREBPs sterol regulatory element-binding proteins  
Yy1 YY1 transcription factor 
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Appendix C: Curriculum Vitae 
 
 
WORK EXPERIENCE   
  
 
 
Tamer Abdelaal 
Narzissenweg Str., 24, 37081 Göttingen (Germany)  
 0049(0)17642004232     0049(0)5513899773     
 Abdelaal@em.mpg.de  
http://www.gpneuro.uni-goettingen.de/content/profile/index.php?ID=2054      
https://www.gpneuro.uni-goettingen.de/students/stud2012/stud_01.php   
 
 
01/10/2014–Present Research Assistant 
Neurogenetics Department, Max Planck Institute of Experimental Medicine, Göttingen (Germany).  
10/12/2009–Present Assistant Researcher 
Chemistry of Natural and Microbial Products Department, Pharmaceutical and Drug Industries 
Division, National Research Center, Cairo (Egypt).  
 
11/10/2011–04/01/2012 Internship 
Laboratoire Universitaire de Biodiversité et d’Ecologie Microbienne, Université de Bretagne 
Occidentale (UBO), Quimper, Brittany (France).  
 
15/10/2010–14/04/2011 Internship 
Redox Biology Center, Structural Biology Lab, Cellular and Molecular Interaction Department, VIB 
institute, Vrije Universiteit Brussel, Brussels (Belgium).  
▪ The main goal of this internship was to learn biochemical techniques dealing with Structural Biology. 
▪ During the internship time, I was involved in two projects: 
a) Chaperone tuned cell free expression system for the production of disulfide rich cancer     
                 related proteins. 
b) Nanobody aided crystallization of human protein disulfide isomerase (PDI). 
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EDUCATION AND 
TRAINING 
  
 
 
 
 
 
 
24/10/2005–07/12/2009 Microbiologist 
Chemistry of Natural and Microbial Products Department, Pharmaceutical and Drug Industries 
Division, National Research Center, Cairo (Egypt).  
 
 
01/10/2014–Present PhD student   
Remyelination and Nerve regeneration group, Neurogenetics Department, Max Planck Institute for 
Experimental Medicine, International Max Planck Research School (IMPRS) for Neurosciences, 
Göttingen (Germany).  
Graduate courses attended: 
Methods courses: Mechanisms of RNA silencing course, expansion microscopy, electroneurography: 
principals and practice, Introduction to R and RNA-seq analysis, Introduction into the bioinformatics 
analysis of next generation sequence data, Next Generation Sequencing (NGS) - Analysis of 
RNAseq and ChIPseq data, Introduction to lipid analysis. 
Soft skills courses: Project management for young scientists. Taking off as a project pilot, Basic 
statistics for graduate students in the life sciences. 
20/08/2012–30/08/2014 European Master Degree in Neurophysiology (Grade:B) Life sciences 
Neurasmus (a European Master in Neuroscience):  
▪ In First year: 
I have completed an intensive curriculum in Neurophysiology (including (3x2 months each) 
lab rotations during my first year in different Neurosciences research disciplines including 
Electrophysiology, Neuroimmunology and Neurogenetics) (90 ECTS in one year) at 
International Max Planck Research School (IMPRS) for Neurosciences, Faculty of Biology 
and Physiology, Georg-August-Universität, Göttingen, Germany. 
▪ In second year: 
Pursued an external semester entitled " Advanced course in Neurosciences and 
Neuropharmacology " at Faculty of Biology, Bordeaux University, France. 
Master thesis at the Neurogenetics Department, Max Planck Institute for Experimental 
Medicine entitled with "The impact of Pmp22 over-expression on peripheral nervous system 
(PNS) myelination in vitro". 
01/10/2005–18/04/2009 Master Degree in Microbiology  
Microbiology & Botany Department, Faculty of Science, Al-Azhar University, Cairo (Egypt).  
 
20/09/2001–30/05/2005 Bachelor's Degree in Science in Microbiology/Chemistry 
(Excellent with honour) 
 
Microbiology & Botany Department, Faculty of Science, Al Azhar University, Cairo (Egypt).  
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ADDITIONAL 
INFORMATION 
  
 
 
Job-related skills Mastered experimental techniques:  
 
Protein biochemistry: Cloning and recombinant proteins expression, purification, 
crystallization trials setup. 
Primary cultures: Schwann cell monocultures, mouse and rat DRG-Schwann cells cocultures 
establishment and using it as an in vitro model for CMT1A to test treatment approaches. 
Experimental therapy trial design and execution: Study plan preparation, motor phenotyping 
tests, surgery to collect different nervous system tissues for further analysis including 
transcription analysis (qRt-PCR), myelin fraction preparation from peripheral nerve, protein 
quantification: western blot  (quantitative and qualitative WB & phospho-WB) and silver gel. 
Histology: Light and electron microscopy, Immunocytochemistry and 
Immunohistochemistry,Fluorescence imaging, Images analysis using ImageJ. 
Electrophysiology: Two-electrode voltage clamp and Electroneurography (of Sciatic nerve 
and tail nerve): Nerve conduction velocity and compound muscle action potential.   
Honours and awards   
▪ Göttingen Graduate School for Neurosciences and Molecular Biosciences (GGNB) Travel Grant 
for attending the 2017 PNS Annual Meeting, Sitges-Barcelona, Spain (8th-12th July, 2017).  
▪ Registration fees waiver for junior presenting author to participate in the 2017 PNS Annual 
Meeting- Sitges-Barcelona, Spain (8th-12th July, 2017). 
▪ Poster Prize at "8th Westerberg Herbsttagung, September 2016" which is a scientific meeting 
organized on the Science Campus of the University of Osnabrück together with the Study Group 
"Molecular Neurobiology" of the GBM (Gesellschaft für Biochemie und Molekularbiologie). 
▪ Registration fee wavier, for outstanding applicant , by the organizing committee for attending the 
Göttingen SPIRIT Summer School (Multimodal molecular imaging: from high resolution in vitro 
towards in vivo imaging), Max Planck Institute for Experimental Medicine, Göttingen (4th -7th 
April, 2016).  
▪ Doctoral grant from Max Planck Society (January 2015-Februray 2015). 
▪ Göttingen Graduate School for Neurosciences and Molecular Biosciences (GGNB) Bridging 
Fund to start PhD Studies at International Max Planck Research School For Neurosciences 
(October2014 - December 2014). 
▪ Erasmus Mundus master Scholarship via Neurasmus Program (August2012 – August 2014). 
▪ Internship at LUBEM institute, Quimper, France funded by Scientific Sector, French Centre for 
Culture and Cooperation (CFCC), Embassy of France in Egypt (September 2011 - January 2012). 
▪ Internship at VIB Department of Molecular and Cellular Interactions, Brussel, Belgium, funded by 
Ministry of Higher Education in Egypt (October 2010 – April 2011). 
Conferences, Scientific 
meetings and PhD 
retreats 
▪ Oral poster presentation at the 2017 PNS Annual Meeting- Sitges-Barcelona (Spain) entitled with 
(Lecithin therapy ameliorates disease progression in a rat model of Charcot Marie Tooth Disease 
1A (CMT1A) (8th-12th July, 2017). 
▪ Oral presentation at the Myelin Meeting in Kassel (Theme: Current Topics in Myelin Research) 
entitled with (Lecithin therapy improves disease progression in a rat model of Charcot Marie 
Tooth Disease 1A (CMT1A) (2nd-4th March, 2017). 
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▪ Poster presentation at "8th Westerberg Herbsttagung" which is a scientific meeting organized on 
the Science Campus of the University of Osnabrück together with the Study Group "Molecular 
Neurobiology" of the GBM (Gesellschaft für Biochemie und Molekularbiologie) (22nd-24th 
September, 2016). 
▪ Oral presentation at the International Max Planck Research School for Neurosciences, Göttingen 
PhD retreat, Spiekeroog (4th -7th April, 2016). The oral presentation was entitled "Glial cell 
differentiation in CMT1A". 
▪ Participation in the Göttingen SPIRIT Summer School (Multimodal molecular imaging: from 
high resolution in vitro towards in vivo imaging), Max Planck Institute for Experimental Medicine, 
Göttingen (4th -7th April, 2016). 
▪ Poster presentation at the Max Planck Institute for Experimental Medicine PhD retreat. The poster 
was entitled with (Impact of Pmp22 overexpression on peripheral nervous system myelination in 
vitro ) Berlin (4th - 7th, April, 2015). 
▪ Oral presentation of master thesis work outcomes at the 3rd Neurasmus Annual Meeting at 
Charité - Universitätsmedizin Berlin and participated in a workshop entitled "Transnational 
Research" (10th – 15th July, 2014).  
▪ Participation in the 2nd Neurasmus annual meeting which was held at the Center For 
Neuroscience and Cell Biology in Coimbra, Portugal (1st-5th July,2013). 
▪ Participation in the 3rd international Brussels' Center for Redox Biology (BCRB) fall symposium 
at Vrije Universiteit Brussel, Belgium ( 3rd of December, 2010). 
 
